var title_f9_35_9776="Asthma peak flow daily diary II";
var content_f9_35_9776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Asthma peak flow daily diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 792px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Woolcock Institute of Medical Research, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9776=[""].join("\n");
var outline_f9_35_9776=null;
var title_f9_35_9777="Midecamycin: International drug information";
var content_f9_35_9777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Midecamycin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aboren (AR);",
"     </li>",
"     <li>",
"      Macropen (HR, JP);",
"     </li>",
"     <li>",
"      Medemycin (JP);",
"     </li>",
"     <li>",
"      Midecin (IT);",
"     </li>",
"     <li>",
"      Miocamen (IT, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Midecamycin Acetate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections caused by susceptible strains of",
"     <i>",
"      Staphylococcus",
"     </i>",
"     ,",
"     <i>",
"      Streptococcus",
"     </i>",
"     ,",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      Mycoplasma",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 900-1800 mg/day in 2-3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 600 mg, 900 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10416 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9777=[""].join("\n");
var outline_f9_35_9777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979554\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979547\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979549\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979552\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979548\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821092\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979551\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10416\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10416|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_35_9778="Apical 4 chamber LA volume by planimetry";
var content_f9_35_9778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Planimetry of the left atrium for volume calculation from the apical 4 chamber view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An end-systolic freeze-frame image from the four chamber view is used to obtain maximum left atrial (LA) volume; panel A is a schematic of the structures imaged and panel B is the actual echocardiogram. The lines shown within the LA in panel C were generated by a light pen digitizing system that allows calculation of a single plane (area-length) volume from the outline shown or the combination of this area-length outline to calculate atrial volume by a modified Simpson's rule or method of discs.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle; RA: right atrium; tv: tricuspid valve; pv: pulmonic valve; R: right; L: left; A: apex; B: base.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9778=[""].join("\n");
var outline_f9_35_9778=null;
var title_f9_35_9779="Ankle sprains PI";
var content_f9_35_9779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Ankle sprains",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 686px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When a person sprains his or her ankle, the ankle joint turns too far in a particular direction. Inside the ankle are tough bands of tissue called ligaments, which hold the different bones together. During a sprain, one or more of those ligaments (shown in white) stretch too far or even tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9779=[""].join("\n");
var outline_f9_35_9779=null;
var title_f9_35_9780="Lymphatic drainage of the esophagus";
var content_f9_35_9780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Lymphatic drainage of the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 687px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9780=[""].join("\n");
var outline_f9_35_9780=null;
var title_f9_35_9781="Umbilical acanthosis nigricans";
var content_f9_35_9781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented, velvety plaque is present on the umbilicus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9781=[""].join("\n");
var outline_f9_35_9781=null;
var title_f9_35_9782="Pediatric subdural hematoma on magnetic resonance imaging";
var content_f9_35_9782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A 6 month old male was imaged for macrocephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T1 (Panel A) and T2 (Panel B)-weighted MRI images show enlargement of the subarachnoid spaces, establishing the diagnosis of benign extra-axial fluid of infancy. Follow up T1 (Panel C) and T2 (Panel D)-weighted images reveal chronic subdural hematoma within the enlarged spaces. The child was completely asymptomatic from this and required no treatment. The areas of hematoma resolved spontaneously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark R Proctor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9782=[""].join("\n");
var outline_f9_35_9782=null;
var title_f9_35_9783="Orbital fractures";
var content_f9_35_9783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Orbital fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Mark I Neuman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9783/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9783/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/35/9783/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although orbital fractures are rarely life-threatening, they may be associated with serious intracranial and ocular injuries that require emergent management. In addition, injuries affecting vision and those with cosmetic implications must be promptly recognized and referred for appropriate treatment.",
"   </p>",
"   <p>",
"    This topic will review the evaluation and management of patients with orbital fractures, mechanisms of injury to the orbit, fracture types, and associated injuries. A rapid overview of essential considerations is provided (",
"    <a class=\"graphic graphic_table graphicRef61925 \" href=\"UTD.htm?28/30/29164\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other facial fractures in adults and children are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=see_link\">",
"       \"Facial trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=see_link\">",
"       \"Nasal trauma and fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=see_link\">",
"       \"Jaw fractures in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence and mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orbital fractures occur more commonly among young adult and adolescent males. In a retrospective series describing 92 adults with orbital fractures, the mean age was 32 years, and 72 percent were male [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1\">",
"     1",
"    </a>",
"    ]. A retrospective series describing orbital fractures in children reported a mean age of 12.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/2\">",
"     2",
"    </a>",
"    ]. Of these children, 81 percent were boys.",
"   </p>",
"   <p>",
"    The low prevalence of orbital fractures among younger children may be related to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The face of a child is relatively small compared with the head, and thus most fractures in young children tend to involve the upper face and skull [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children, the proportion of cancellous to cortical bone is greater, providing more elasticity to the facial bones. In addition, sinus cavities are poorly developed. However, pneumatization of the frontal sinus may actually be protective for adults with injury to the superior orbital rim. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Orbital roof fracture'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A prominent buccal fat pad affords some protection to the malar region of the face.",
"     </li>",
"     <li>",
"      Children are less likely to be exposed to occupational trauma, assaults, and major trauma associated with motor vehicle crashes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among adults with orbital fractures, the most frequent mechanisms of injury are assaults and motor vehicle crashes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. For children, these injuries generally occur during sports (particularly baseball or softball) or play [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant force is required to produce orbital fractures. Consequently, serious associated injuries can occur. Specific injuries include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracranial injury &ndash; Central nervous system (CNS) injury may occur among patients hospitalized with orbital fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1,5,6\">",
"       1,5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intraocular injury &ndash; Injury to the globe (such as ruptured globe, hyphema, or injury to the retina) can occur in association with an orbital fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In a case series describing adult patients with orbital fracture, 29 percent had a significant intraocular injury [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/7\">",
"       7",
"      </a>",
"      ]. In a retrospective series describing children with orbital fractures treated at a specialty hospital, 50 percent had associated eye injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"       \"Traumatic hyphema: Clinical features and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orbit is formed primarily by five bones of the skull (",
"    <a class=\"graphic graphic_table graphicRef64094 \" href=\"UTD.htm?9/24/9611\">",
"     table 2",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef60058 \" href=\"UTD.htm?18/36/19008\">",
"     figure 1",
"    </a>",
"    ). Other nearby structures that must be considered when evaluating a patient with an orbital fracture include the following (",
"    <a class=\"graphic graphic_figure graphicRef72674 \" href=\"UTD.htm?29/54/30566\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extraocular muscles",
"     </li>",
"     <li>",
"      Sinuses",
"     </li>",
"     <li>",
"      Medial and lateral canthal (palpebral) ligaments (which maintain the shape of the palpebral fissure)",
"     </li>",
"     <li>",
"      Lacrimal duct system",
"     </li>",
"     <li>",
"      Infraorbital and supraorbital nerves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The thick frontal bone forms the superior orbital rim and the roof of the orbit. The frontal sinus is adjacent to the superior medial portion of the roof of the orbit. The supraorbital nerve runs through the supraorbital notch, which is located at the junction of the medial and middle thirds of the superior orbital rim.",
"   </p>",
"   <p>",
"    The greater wing of the sphenoid bone and the zygoma (which is relatively thick) form the lateral wall of the orbit. The lateral canthal ligament attaches to the zygoma.",
"   </p>",
"   <p>",
"    The zygoma and the thin maxillary bone comprise the infraorbital rim and the floor of the orbit. The inferior oblique and inferior rectus muscles lie above the floor of the orbit. The maxillary sinus is beneath the orbital floor. The infraorbital nerve travels in a groove in the maxillary bone, further weakening it.",
"   </p>",
"   <p>",
"    The maxillary and ethmoid bones form the medial wall of the orbit. The medial rectus muscle is adjacent to the medial wall, which overlies the ethmoid sinus. The medial canthal ligament attaches to the maxillary bone. The lacrimal duct system overlies the maxillary bone beneath the medial canthal ligament.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FRACTURE TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the orbit may involve one or more of the walls of the orbit, the orbital rim, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1\">",
"     1",
"    </a>",
"    ]. Factors that influence the location and extent of the fracture include the mechanism of injury and the age of the patient. Injury to adjacent structures can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Orbital zygomatic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common fracture of the orbital rim is in the orbital zygomatic region. This injury is typically the result of a high-impact blow to the lateral orbit. There is often an associated fracture of the orbital floor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nasoethmoid fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures in the nasoethmoidal region of the medial orbital rim are also common. In a retrospective series of adult patients, 32 percent of fractures occurred in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1\">",
"     1",
"    </a>",
"    ]. Fracture of the maxillary bone in this portion of the orbital rim can result in disruption of the medial canthal ligament and the lacrimal duct system. In addition, the medial rectus muscle may become trapped in fractures of the medial wall of the orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Orbital floor fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the floor of the orbit, sometimes known as \"blowout fractures,\" typically occur when a small round object, such as a baseball, strikes the eye. Experimental evidence suggests that orbital floor fractures may be caused by one or both of the following mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased intraocular pressure as the result posterior displacement of the globe (hydraulic theory)",
"     </li>",
"     <li>",
"      A direct blow to the infraorbital rim",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among children, the floor of the orbit is more flexible. Consequently, it may fracture in a linear pattern that snaps back to create a \"trap-door\" fracture. In adults, the floor of the orbit is thinner and more likely to shatter when exposed to force [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significant consequence of fractures of the orbital floor is entrapment of the inferior rectus muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    orbital fat (",
"    <a class=\"graphic graphic_picture graphicRef79690 \" href=\"UTD.htm?3/47/3838\">",
"     picture 1",
"    </a>",
"    ). Ischemia and subsequent loss of muscle function may occur either because of entrapment of muscle within the fracture fragment (more likely in children), or as the result of edema and hemorrhage of muscle and extraocular fat that have prolapsed through the fracture into the maxillary sinus (more likely in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/4,11-13\">",
"     4,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enophthalmos (the eye is receded into the orbit) may develop when the globe is displaced posteriorly in association with an orbital floor fracture and prolapse of tissue into the maxillary sinus. Orbital dystopia (the eye on the affected side is lower in the horizontal plane than the other) may occur because entrapped muscle and orbital fat pull the eye downward.",
"   </p>",
"   <p>",
"    Injury to the infraorbital nerve (resulting in decreased sensation along the cheek, upper lip, or upper gingiva) may occur as the result of an orbital floor fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Orbital roof fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orbital roof fractures are more common in younger patients (less than 10 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This phenomenon is probably related to the high cranium-to-midface ratio of young children as compared with adults (thus exposing a larger upper surface for injury). In addition, pneumatization of the frontal sinus helps the adult skull dissipate energy from forces to the superior orbital rim. As expected, orbital roof fractures have a high association with intracranial injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first priority in the evaluation of patients who may have orbital fractures is to identify life-threatening",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serious associated injuries. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Associated injuries'",
"    </a>",
"    above.) Patients with a possible injury to the cervical spine should be properly immobilized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient's condition has been stabilized, careful evaluation of the orbital injury may proceed. Injuries that threaten the globe must be urgently identified and treated. These include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ruptured globe",
"     </li>",
"     <li>",
"      Orbital hematoma",
"     </li>",
"     <li>",
"      Optic nerve sheath hematoma",
"     </li>",
"     <li>",
"      Retinal detachment",
"     </li>",
"     <li>",
"      Hyphema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Historical details and findings on physical examination should identify patients likely to have an orbital fracture. Common signs and symptoms of orbital fracture include periocular ecchymosis, diplopia, decreased sensation in the distribution of the infraorbital nerve, and orbital emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injuries related to the fracture must also be identified. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Entrapment of extraocular muscle",
"     </li>",
"     <li>",
"      Fracture into a sinus",
"     </li>",
"     <li>",
"      Injury to the medial canthal ligament",
"     </li>",
"     <li>",
"      Injury to the lacrimal duct system",
"     </li>",
"     <li>",
"      Intraocular injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging of the orbit with computed tomography (CT) should be performed to localize the fracture and identify associated injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific information regarding when the injury occurred, area of the face that was injured, and the mechanism of injury should be obtained. Key questions for patients who are alert and verbal include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Where does it hurt?",
"     </li>",
"     <li>",
"      Do you have blurry, double, or decreased vision?",
"     </li>",
"     <li>",
"      Do you have difficulty with eye movement or double-vision in a specific direction?",
"     </li>",
"     <li>",
"      Do you have numbness of a particular region of your face?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diffuse pain occurs with an orbital hematoma, whereas pain with eye movement suggests injury involving extraocular muscles. Any change in vision could indicate a serious intraocular injury. Diplopia, particularly with upward gaze, and numbness below the eye may occur with fractures of the orbital floor. Numbness of the forehead suggests damage to the supraorbital nerve as the result of injury to the superior orbital rim or roof of the orbit.",
"   </p>",
"   <p>",
"    Nausea and vomiting are common following eye injury. In addition, entrapment of extraocular muscles can stimulate the oculocardiac reflex, producing bradycardia, as well as nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient has been evaluated for life-threatening injuries, a focused examination of the facial bones, soft tissues surrounding the eye, and the eye itself should be performed. The eye should be examined as quickly as possible since subsequent soft tissue swelling may make it difficult to separate the eyelids. Care should be taken not to put pressure on the eye, which, in the presence of a globe rupture, could cause extrusion of intraocular contents.",
"   </p>",
"   <p>",
"    Deformity involving any of the facial bones should be noted. Tenderness, crepitus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    step-off on palpation of the malar eminences, zygomatic arches, or orbital rims may indicate an underlying fracture.",
"   </p>",
"   <p>",
"    Examination of the eyelids and surrounding soft tissue may demonstrate crepitance, indicating orbital emphysema as the result of fracture into a sinus. Injury to the lacrimal ducts can occur as the result of lacerations or soft tissue injury along the medial canthus. Decreased sensation indicates injury to the supraorbital nerve (forehead) or infraorbital nerve (cheek).",
"   </p>",
"   <p>",
"    On inspection of the globe, the following features are indications of significant injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proptosis (orbital hematoma)",
"     </li>",
"     <li>",
"      Extrusion of intraocular contents, severe conjunctival hemorrhage,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a tear-shaped pupil (ruptured globe)",
"     </li>",
"     <li>",
"      Widened intercanthal distance (disruption of medial canthal ligament)",
"     </li>",
"     <li>",
"      Orbital dystopia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      enophthalmos (orbital floor fracture)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pupillary reactivity, size, and shape, as well as extraocular movements and visual acuity should be evaluated. Funduscopic examination may identify vitreous hemorrhage or retinal injury. Finally, a slit-lamp examination should be performed whenever possible. Injuries that may be identified with the slit-lamp include hyphema, iritis, lens dislocation, and ruptured globe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thin cut coronal computed tomography (CT) of the orbit is the imaging modality of choice to diagnose orbital fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53238 \" href=\"UTD.htm?24/26/24992\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71183 \" href=\"UTD.htm?19/9/19614\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, CT may distinguish orbital edema from entrapped extraocular muscle for patients with diplopia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limitation of eye movement.",
"   </p>",
"   <p>",
"    CT should be performed for a patient with orbital trauma with any of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evidence of a fracture on physical examination",
"     </li>",
"     <li>",
"      Limitation of extraocular motility",
"     </li>",
"     <li>",
"      Decreased visual acuity",
"     </li>",
"     <li>",
"      Severe pain",
"     </li>",
"     <li>",
"      Inadequate examination (usually because of soft tissue swelling), particularly in patients with altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity of plain radiographs for detecting orbital fractures is poor (about 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, plain radiographs are often difficult to interpret and are inadequate to determine whether or not a patient requires operative intervention. They may be useful as a screening tool when CT is unavailable or for children with a minor mechanism of injury who would require sedation for CT. Clouding of the maxillary sinus indicates the possibility of blood or orbital fat in the sinus as the result of an orbital floor fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial priority for the management of patients with orbital fracture is to identify and treat life-threatening conditions. An ophthalmologist should be consulted during the initial evaluation in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Globe injuries (orbital or optic sheath hematoma, ruptured globe) &ndash; Emergent management of these injuries includes protection of the globe, elevation of the head, intravenous fluids as indicated for nausea and vomiting, and pain control. Patients with orbital hematomas may require an emergent lateral canthotomy to decompress the orbit. However, this definitive procedure should be performed by an ophthalmologist, whenever possible.",
"     </li>",
"     <li>",
"      Severe vagal symptoms (nausea, vomiting, bradycardia) associated with extraocular muscle entrapment &ndash; Severe vagal symptoms, in the absence of intracranial injury, may be caused by the oculocardiac reflex associated with extraocular muscle entrapment. These debilitating symptoms are usually relieved with release of the muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/17,19\">",
"       17,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A specialist (generally an ophthalmologist or plastic surgeon) should be consulted to arrange for follow-up within 24 hours for patients with these injuries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle entrapment as the result of orbital floor or medial wall fractures (",
"      <a class=\"graphic graphic_picture graphicRef79690 \" href=\"UTD.htm?3/47/3838\">",
"       picture 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/4,9,18,20-23\">",
"       4,9,18,20-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enophthalmos or orbital dystopia that results in significant facial asymmetry [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Naso-orbital-ethmoid fractures with injury to the medial canthal ligament",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lacrimal apparatus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General management principles for patients with orbital fractures include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should have follow-up within one week with an ophthalmologist.",
"     </li>",
"     <li>",
"      Prophylactic oral antibiotics to cover sinus pathogens are generally recommended for patients with orbital fracture into a sinus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/11,25\">",
"       11,25",
"      </a>",
"      ]. There is limited evidence to support or refute this practice [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/26\">",
"       26",
"      </a>",
"      ]. Specific antibiotic choices include either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Some experts advocate treatment of patients with limitation of extraocular movement with oral corticosteroids to decrease swelling [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/11,25\">",
"       11,25",
"      </a>",
"      ]. The following evidence supports this practice:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A small randomized trial among patients with orbital fractures reported quicker resolution of diplopia among those who were treated with corticosteroids compared with those who were not [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another small, randomized trial among patients with orbital floor injuries requiring surgical exploration found that postoperative swelling decreased more rapidly among those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      compared with those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cold packs may be applied over the eye for the first 48 hours to reduce swelling. In addition, patients should sleep with the head of the bed elevated and avoid nose blowing and sniffing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe fractures, particularly in the zygomatic-maxillary or nasal-ethmoid regions, often have significant disruption of the orbit, with injury to associated structures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical repair is typically complex, and residual visual and cosmetic defects may occur. Patients with orbital floor fractures who have eye muscle dysfunction, enophthalmos, or orbital dystopia usually require surgery and should be promptly referred to an ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Substantial morbidity from vision loss may occur following even mild to moderate blunt eye trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9783/abstract/7\">",
"     7",
"    </a>",
"    ]. Loss of vision can occur either as a result of direct ocular injury (such as with retinal detachment) or vascular compromise to the optic nerve (as may occur in association with an orbital or optic nerve sheath hematoma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=see_link\">",
"       \"Patient information: Skull and facial fractures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/62/13281?source=see_link\">",
"       \"Patient information: Black eye (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orbital fractures occur most commonly in adolescent and young adult males. Mechanisms of injury include motor vehicle collisions, assaults, and sports-related injuries. Because of the significant amount of force involved with these mechanisms, associated intracranial and intraocular injuries occur frequently (",
"    <a class=\"graphic graphic_figure graphicRef60058 \" href=\"UTD.htm?18/36/19008\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72674 \" href=\"UTD.htm?29/54/30566\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injuries that threaten vision or may result in significant poor functional or cosmetic outcomes must be identified. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination should include assessment of visual acuity and extraocular motor function. A slit-lamp examination should be performed, whenever possible. The following physical findings are significant (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical examination'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Proptosis (orbital hematoma)",
"     </li>",
"     <li>",
"      Extrusion of intraocular contents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tear-shaped pupil (ruptured globe)",
"     </li>",
"     <li>",
"      Widened intercanthal distance (disruption of medial canthal ligament)",
"     </li>",
"     <li>",
"      Orbital dystopia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      enophthalmos (orbital floor fracture)",
"     </li>",
"     <li>",
"      Limitation of extraocular motility (entrapped muscle) (",
"      <a class=\"graphic graphic_picture graphicRef79690 \" href=\"UTD.htm?3/47/3838\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Decreased visual acuity (intraocular injury or injury to the optic nerve)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging with thin cut coronal computed tomography (CT) should be performed for patients with any of these findings (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53238 \" href=\"UTD.htm?24/26/24992\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71183 \" href=\"UTD.htm?19/9/19614\">",
"       image 2",
"      </a>",
"      ). In addition, patients with deformity, crepitance, or step-off on palpation of facial bones should receive an orbital CT. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with injuries to the globe should be emergently evaluated by an ophthalmologist. Those with severe vagal symptoms (nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bradycardia) as the result of extraocular muscle entrapment, should also see an ophthalmologist emergently. An ophthalmologist should evaluate those with evidence of muscle entrapment, enophthalmos, orbital dystopia, or injury to the medial canthal ligament",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lacrimal apparatus within 24 hours. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with orbital fractures that involve a sinus receive antibiotic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Specific antibiotic choices include either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . We also suggest that most patients with orbital fractures with limitation of extraocular movement receive corticosteroids to reduce swelling (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31520937\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/1\">",
"      Manolidis S, Weeks BH, Kirby M, et al. Classification and surgical management of orbital fractures: experience with 111 orbital reconstructions. J Craniofac Surg 2002; 13:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/2\">",
"      Hatton MP, Watkins LM, Rubin PA. Orbital fractures in children. Ophthal Plast Reconstr Surg 2001; 17:174.",
"     </a>",
"    </li>",
"    <li>",
"     Neuman MI, Eriksson E. Facial trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher G, Henretig R.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.1475.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/4\">",
"      Cruz AA, Eichenberger GC. Epidemiology and management of orbital fractures. Curr Opin Ophthalmol 2004; 15:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/5\">",
"      Koltai PJ, Amjad I, Meyer D, Feustel PJ. Orbital fractures in children. Arch Otolaryngol Head Neck Surg 1995; 121:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/6\">",
"      Donahue DJ, Smith K, Church E, Chadduck WM. Intracranial neurological injuries associated with orbital fracture. Pediatr Neurosurg 1997; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/7\">",
"      Kreidl KO, Kim DY, Mansour SE. Prevalence of significant intraocular sequelae in blunt orbital trauma. Am J Emerg Med 2003; 21:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/8\">",
"      Umeed S, Shafquat S. Commotio-retinae and central retinal artery occlusion after blunt ocular trauma. Eye (Lond) 2004; 18:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/9\">",
"      Segrest DR, Dortzbach RK. Medial orbital wall fractures: complications and management. Ophthal Plast Reconstr Surg 1989; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/10\">",
"      Ahmad F, Kirkpatrick NA, Lyne J, et al. Buckling and hydraulic mechanisms in orbital blowout fractures: fact or fiction? J Craniofac Surg 2006; 17:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/11\">",
"      Jatla KK, Enzenauer RW. Orbital fractures: a review of current literature. Curr Surg 2004; 61:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/12\">",
"      Smith B, Lisman RD, Simonton J, Della Rocca R. Volkmann's contracture of the extraocular muscles following blowout fracture. Plast Reconstr Surg 1984; 74:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/13\">",
"      Lisman RD, Smith BC, Rodgers R. Volkmann's ischemic contractures and blowout fractures. Adv Ophthalmic Plast Reconstr Surg 1987; 7:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/14\">",
"      Long J, Tann T. Orbital trauma. Ophthalmol Clin North Am 2002; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/15\">",
"      Brady SM, McMann MA, Mazzoli RA, et al. The diagnosis and management of orbital blowout fractures: update 2001. Am J Emerg Med 2001; 19:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/16\">",
"      Cohen SM, Garrett CG. Pediatric orbital floor fractures: nausea/vomiting as signs of entrapment. Otolaryngol Head Neck Surg 2003; 129:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/17\">",
"      Egbert JE, May K, Kersten RC, Kulwin DR. Pediatric orbital floor fracture : direct extraocular muscle involvement. Ophthalmology 2000; 107:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/18\">",
"      Burnstine MA. Clinical recommendations for repair of orbital facial fractures. Curr Opin Ophthalmol 2003; 14:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/19\">",
"      Bansagi ZC, Meyer DR. Internal orbital fractures in the pediatric age group: characterization and management. Ophthalmology 2000; 107:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/20\">",
"      Otori N, Haruna S, Moriyama H. Endoscopic endonasal or transmaxillary repair of orbital floor fracture: a study of 88 patients treated in our department. Acta Otolaryngol 2003; 123:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/21\">",
"      Chang EL, Bernardino CR. Update on orbital trauma. Curr Opin Ophthalmol 2004; 15:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/22\">",
"      Matteini C, Renzi G, Becelli R, et al. Surgical timing in orbital fracture treatment: experience with 108 consecutive cases. J Craniofac Surg 2004; 15:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/23\">",
"      Hollier LH, Thornton J, Pazmino P, Stal S. The management of orbitozygomatic fractures. Plast Reconstr Surg 2003; 111:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/24\">",
"      Becelli R, Renzi G, Mannino G, et al. Posttraumatic obstruction of lacrimal pathways: a retrospective analysis of 58 consecutive naso-orbitoethmoid fractures. J Craniofac Surg 2004; 15:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/25\">",
"      Courtney DJ, Thomas S, Whitfield PH. Isolated orbital blowout fractures: survey and review. Br J Oral Maxillofac Surg 2000; 38:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/26\">",
"      Martin B, Ghosh A. Antibiotics in orbital floor fractures. Emerg Med J 2003; 20:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/27\">",
"      Millman AL, Della Rocca RC, Spector S, et al. Steroids and orbital blowout fractures--a new systematic concept in medical management and surgical decision-making. Adv Ophthalmic Plast Reconstr Surg 1987; 6:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9783/abstract/28\">",
"      Flood TR, McManners J, el-Attar A, Moos KF. Randomized prospective study of the influence of steroids on postoperative eye-opening after exploration of the orbital floor. Br J Oral Maxillofac Surg 1999; 37:312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6546 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9783=[""].join("\n");
var outline_f9_35_9783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence and mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FRACTURE TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Orbital zygomatic fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nasoethmoid fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Orbital floor fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Orbital roof fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31520937\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6546|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/26/24992\" title=\"diagnostic image 1\">",
"      Orbital floor fracture entrapment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/9/19614\" title=\"diagnostic image 2\">",
"      Orbital floor fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6546|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/36/19008\" title=\"figure 1\">",
"      Orbital bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/54/30566\" title=\"figure 2\">",
"      Orbital structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6546|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/47/3838\" title=\"picture 1\">",
"      Extraocular muscle entrapment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/30/29164\" title=\"table 1\">",
"      Orbital fracture overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/24/9611\" title=\"table 2\">",
"      Anatomy of orbit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/49/7962?source=related_link\">",
"      Facial trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6615?source=related_link\">",
"      Jaw fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33575?source=related_link\">",
"      Nasal trauma and fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/62/13281?source=related_link\">",
"      Patient information: Black eye (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/24/34178?source=related_link\">",
"      Patient information: Skull and facial fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_35_9784="Easy bruising";
var content_f9_35_9784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Easy bruising",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9784/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9784/contributors\">",
"     Eric H Kraut, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9784/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9784/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/35/9784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7213103\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Easy bruising is a common complaint in medical practice for both primary care clinicians and hematologists. Easy bruising can be defined as bruising without a history of trauma or bruising after minor trauma that would not have caused bruising in the past. Differentiating between bruising that might be considered normal versus clinically significant is challenging given that there may not be specific signs and symptoms.",
"   </p>",
"   <p>",
"    This topic will describe particular aspects of the clinical evaluation that can aid a provider in distinguishing bruising that is due to a pathologic versus a benign process. Specific disorders associated with bruising and the approach to patients with a bleeding diathesis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=see_link\">",
"     \"Clinical manifestations and evaluation of thrombocytopenia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428230978\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one United States survey of 500 healthy, ethnically-diverse adults, 18 percent of individuals reported easy bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/1\">",
"     1",
"    </a>",
"    ]. This finding is consistent with many other studies in which the frequency of easy bruising in healthy individuals ranged from 12 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Women are more likely than men to report easy bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213111\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bruise (ecchymosis) is a collection of blood beneath the skin, resulting from extravasation of blood from surrounding vessels. Easy bruising can result from abnormalities affecting the blood vessels themselves, the surrounding skin and subcutaneous structures, platelet number and function, or coagulation cascade function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical injury to a blood vessel normally triggers a vigorous physiologic response. Damage to endothelial tissue causes activation and adhesion of circulating platelets with the assistance of von Willebrand factor. This in turn results in the rapid formation of a platelet plug at the site of injury. Stabilization of the plug via fibrin deposition subsequently results from activation of the coagulation cascade (",
"    <a class=\"graphic graphic_figure graphicRef75450 \" href=\"UTD.htm?12/20/12610\">",
"     figure 1",
"    </a>",
"    ). A problem or defect at any step of this process will increase the risk of abnormal bruising and bleeding, regardless of the degree of trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428230883\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of bruising can be broadly classified by the",
"    <span class=\"nowrap\">",
"     anatomic/physiologic",
"    </span>",
"    defenses against bleeding (",
"    <a class=\"graphic graphic_table graphicRef67597 \" href=\"UTD.htm?1/47/1790\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/5\">",
"     5",
"    </a>",
"    ]. The following list includes the main categories with their most commonly-associated etiologies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disorders of blood vessels and surrounding tissue (eg, physical abuse, vitamin C deficiency, connective tissue disease)",
"     </li>",
"     <li>",
"      Platelet abnormalities (eg, drugs, systemic illness including infections, von Willebrand disease) (",
"      <a class=\"graphic graphic_table graphicRef73534 \" href=\"UTD.htm?35/39/36477\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coagulation disorders (eg, coagulation factor deficiency, liver disease, vitamin K deficiency)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428230906\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As bruising is a common complaint, the clinician should be familiar with important signs and symptoms that require further workup. The history and physical examination are more useful than laboratory testing in this assessment. The principal goal of the clinical history and examination is to distinguish easy bruising from normal bruising, from other skin lesions that can be mistaken for bruising, and from physical abuse. Laboratory testing is used in selected cases for further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213118\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history is integral to a successful evaluation, and helps to avoid unnecessary laboratory testing. Questionnaires used in hematology clinics can help identify individuals who need further workup; however, these questionnaires tend to be detailed and their usefulness is still being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2061949\">",
"    <span class=\"h3\">",
"     Associated trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first questions that should be asked is whether there was any trauma associated with the bruises. Normal bruising is to be expected with moderate to severe trauma. Easy bruising is suspected when the patient denies any history of trauma or if there is bruising out of proportion to mild trauma. By definition, easy bruising is not associated with moderate to severe trauma.",
"   </p>",
"   <p>",
"    A lack of physical trauma related to a bruise raises suspicion of an underlying bleeding diathesis. However, this can sometimes be misleading. Some patients, particularly those who are fair skinned, overweight, and female can develop bruising with minimal trauma, and may not remember being injured.",
"   </p>",
"   <p>",
"    In the setting of physical abuse, a history of physical trauma may not be volunteered. Young children, women, and elderly persons are at higher risk for nonaccidental trauma. It may be helpful to interview the patient without the presence of the patient&rsquo;s caregiver or partner to help determine if the patient has been abused. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H4#H4\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link&amp;anchor=H8920150#H8920150\">",
"     \"Intimate partner violence: Diagnosis and screening\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link&amp;anchor=H18#H18\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\", section on 'Screening and assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2062026\">",
"    <span class=\"h3\">",
"     Location and severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of bruising on the distal extremities suggests normal bruising, likely due to known or unknown trauma with activity (eg, falls, sports, bumping into furniture). In contrast, easy bruising usually occurs on multiple areas of the body.",
"   </p>",
"   <p>",
"    Severity and frequency are also important; patients with generalized bruising",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large, frequent bruises may be more likely to have a true bleeding disorder. Easy bruising is considered significant when there are five or more bruises greater than 1 cm in diameter (as defined by the International Society of Thrombosis and Hemostasis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213125\">",
"    <span class=\"h3\">",
"     Bleeding history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any history of significant bleeding that accompanies bruising should alert the clinician to an underlying bleeding disorder. &nbsp;",
"   </p>",
"   <p>",
"    A patient's prior history of invasive procedures or surgery, including dental work and past deliveries, should be obtained. Procedures requiring transfusion raise the index of suspicion regarding an underlying hemorrhagic tendency. Inquiring whether the bleeding was immediate or delayed can also be helpful; disorders associated with platelet dysfunction may demonstrate immediate bleeding, compared to a more delayed onset with coagulation cascade disorders (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7213111\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A history of surgical procedures or other major injury without abnormal bleeding is good evidence against the presence of a significant inherited bleeding disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Patient history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The age of onset of symptoms may distinguish between a congenital versus an acquired bleeding disorder. Problems with bruising since childhood suggest a possible congenital disorder. In contrast, onset of symptoms in middle age or later suggests an acquired condition or comorbid state.",
"   </p>",
"   <p>",
"    The menstrual history may also help identify a bleeding disorder. A female patient may notice that problems with bleeding started during menarche. Menorrhagia (menstrual flow that does not taper after more than three days) and metrorrhagia (bleeding in between periods) are common in women with bleeding disorders.",
"   </p>",
"   <p>",
"    The patient should also be asked about bleeding with minor injuries (eg, shaving, cuts, falls). Associated bleeding from other sites (eg, recurrent epistaxis, gingival bleeding, hemarthrosis) should prompt further investigation for an underlying bleeding disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213139\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed inventory of medication exposures should include prescriptions drugs, over-the-counter medications, and dietary supplements (eg, vitamin E, ginger, gingko). Several medications are associated with an increased risk of bruising (",
"    <a class=\"graphic graphic_table graphicRef73534 \" href=\"UTD.htm?35/39/36477\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Drug-related bruising is most commonly due to nonsteroidal anti-inflammatory drugs (NSAIDS), anticoagulant medications, antiplatelet agents, and glucocorticoids. Other commonly-used, but less-recognized, agents include antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ) and antibiotics (eg, penicillins, cephalosporins).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213146\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bruising can result from a number of underlying nutritional problems, including deficiencies of dietary protein, vitamin C, and vitamin K. These deficiencies are less common in more developed countries where these nutrients are readily accessible in the average diet. However, certain populations may be prone to these nutritional deficiencies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein malnutrition is more common in less developed countries where access to protein-rich foods is limited and among individuals with specialized diets who avoid protein. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link&amp;anchor=H2#H2\">",
"       \"Malnutrition in developing countries: Clinical assessment\", section on 'Protein-energy malnutrition'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"       \"Healthy diet in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin C deficiency, or scurvy, occurs mostly in severely malnourished individuals, including institutionalized, chronically ill patients and those with alcohol abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link&amp;anchor=H54#H54\">",
"       \"Overview of water-soluble vitamins\", section on 'Vitamin C (ascorbic acid)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin K deficiency is more common among those with bacterial overgrowth, celiac disease, chronic pancreatitis, inflammatory bowel disease, and alcohol abuse. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of vitamin K\", section on 'Deficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213153\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be asked if there is any easy bruising or bleeding among the patient&rsquo;s family members. A family with only males affected suggests an X-linked disorder such as factor VIII or factor IX deficiency. In contrast, a family with males and females affected equally suggests an autosomal disorder such as von Willebrand factor deficiency, which is the most common congenital disorder of hemostasis. The less common disorders, such as inherited factor V and factor XI deficiencies, have a similar autosomal inheritance pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link\">",
"     \"Factor XI deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213160\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of bruising may assist with diagnosis of the underlying etiology. Bruises should be distinguished from other forms of subcutaneous bleeding, which may also occur along with bruising. The presence of other examination findings may also help narrow the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8756663\">",
"    <span class=\"h3\">",
"     Appearance and distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of bruising can be helpful. Bruises related to normal physical activities tend to appear on distal upper and lower extremities. For children ages one to three years, bruises are commonly found on the anterior tibia and knee, followed by upper legs and forehead, as a result of falling from learning how to walk or run. Older patients may be at increased risk of bruising from falls and poor tissue turgor, leading to bruises over the upper extremities when being assisted with ambulation.",
"   </p>",
"   <p>",
"    Bruises appearing on the trunk, back, or face should raise one&rsquo;s suspicion of an underlying bleeding disorder,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the possibility of physical abuse in both children and older adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H4#H4\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link&amp;anchor=H8920150#H8920150\">",
"     \"Intimate partner violence: Diagnosis and screening\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link&amp;anchor=H12#H12\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\", section on 'Skin findings'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The color of the bruising may indicate how long ago a traumatic injury occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/5\">",
"     5",
"    </a>",
"    ]. Most bruises are often characterized as &lsquo;black and blue.&rsquo; Within a day or two of onset, bruising may be red-brown. Over several days, bruises can turn to green as hemoglobin is converted to biliverdin, and then yellow as biliverdin is catabolized to bilirubin.",
"   </p>",
"   <p>",
"    Bruises should be distinguished from telangiectasias. Whereas bruises are generally dark and dull in color, telangiectasias are bright and usually red (",
"    <a class=\"graphic graphic_picture graphicRef52483 \" href=\"UTD.htm?36/32/37376\">",
"     picture 1",
"    </a>",
"    ). Telangiectasias over the lips, tongue, nasal cavity, and skin are indicative of hereditary hemorrhagic telangiectasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link&amp;anchor=H8#H8\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2062151\">",
"    <span class=\"h3\">",
"     Other forms of bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal bruising from trauma can be confused with other types of bleeding, including petechiae and purpura. Normal bruises are usually small and superficial in depth. They do not spread into deeper tissues beyond the skin. The presence of petechiae and purpura suggest a bleeding disorder rather than normal bruising.",
"   </p>",
"   <p>",
"    Petechiae are small capillary hemorrhages that appear smaller than bruises. They characteristically develop in crops in areas of increased venous pressure, such as the dependent parts of the body (",
"    <a class=\"graphic graphic_picture graphicRef73905 \" href=\"UTD.htm?14/62/15330\">",
"     picture 2",
"    </a>",
"    ). Petechiae are the smallest bleeding lesions (pinhead in size), and suggest problems with platelet number or function. Petechiae are not normal and always need to be further evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Petechiae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Petechiae'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Purpura are larger in size than petechiae with variable shape and involve bleeding into subcutaneous tissues. Purpura can be seen in a variety of bleeding disorders, including thrombocytopenia and coagulation cascade disorders. Palpable purpura can be seen in vasculitic processes such as Henoch-Sch&ouml;nlein purpura (",
"    <a class=\"graphic graphic_picture graphicRef72094 \" href=\"UTD.htm?41/46/42721\">",
"     picture 3",
"    </a>",
"    ). These lesions may also be painful or tender. An underappreciated phenomenon is so-called &lsquo;senile purpura,&rsquo; which is seen in patients over age 65 years (",
"    <a class=\"graphic graphic_picture graphicRef54977 \" href=\"UTD.htm?39/62/40943\">",
"     picture 4",
"    </a>",
"    ). Senile purpura are non-palpable, purple bruises with small red patches, which fade to brown over a span of a few weeks. They are found on the forearms and legs due to loss of subcutaneous tissue with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/7\">",
"     7",
"    </a>",
"    ]. Psychogenic purpura is a rare and poorly understood clinical presentation of unexplained painful lesions, mostly on the extremities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the face, and is virtually always associated with psychiatric illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26841?source=see_link\">",
"     \"Evaluation of purpura in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Purpura'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the patient with macular skin lesions\", section on 'Solar purpura (senile purpura)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15048?source=see_link\">",
"     \"Psychogenic purpura (Gardner-Diamond syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemarthrosis, or bleeding into a joint space, is always abnormal and indicative of a bleeding disorder. Hemarthrosis is commonly seen with coagulation disorders (eg, factor VIII, IX, and XI deficiencies). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=see_link&amp;anchor=H10#H10\">",
"     \"Hemarthrosis\", section on 'Bleeding disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of any of these clinical examination findings, along with pertinent positive findings from the bleeding history, can help differentiate between platelet versus clotting factor disorders (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2062246\">",
"    <span class=\"h3\">",
"     Other examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific non-dermatologic findings can also be informative and should be assessed during the physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphadenopathy may indicate infection, connective tissue disease, or lymphoid malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=see_link\">",
"       \"Approach to the child with peripheral lymphadenopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"       \"Evaluation of peripheral lymphadenopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatosplenomegaly may indicate systemic disease or chronic liver disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"       \"Coagulation abnormalities in patients with liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypermobile joints or skin hyperelasticity can be seen with Ehlers-Danlos syndrome. Bruising in patients affected with the syndrome appears to be due to decreased connective tissue support surrounding a traumatized vessel.",
"     </li>",
"     <li>",
"      Mitral valve prolapse and joint laxity are commonly seen in patients with Marfan&rsquo;s syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H1393404#H1393404\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Clinical manifestations of MFS'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other physical signs associated with rare conditions are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef67597 \" href=\"UTD.htm?1/47/1790\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7213167\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation for bruising should be considered as an adjunct to performing a good history and physical examination. The laboratory evaluation of patients undergoing preoperative testing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H6#H6\">",
"     \"Preoperative assessment of hemostasis\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No immediate workup is necessary in patients who meet all of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distribution of bruising mainly along distal extremities,",
"     </li>",
"     <li>",
"      No other evidence of bleeding (eg, recurrent epistaxis, gingival bleeding, hemarthrosis), and",
"     </li>",
"     <li>",
"      No personal or family history of significant bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all others, baseline assays including a complete blood count (CBC) with differential and platelet count, prothrombin time (PT), and activated partial thromboplastin (PTT) time should be performed as initial testing.",
"   </p>",
"   <p>",
"    Determining which patients should proceed to further laboratory evaluation after initial testing is important as subsequent testing may cost thousands of dollars in many cases, without any change in management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18063522\">",
"    <span class=\"h3\">",
"     CBC, PT, and PTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the CBC, PT,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PTT are common among patients with bleeding disorders.",
"   </p>",
"   <p>",
"    If thrombocytopenia is detected, a peripheral blood smear should also be performed to help to rule out pseudothrombocytopenia and to look for abnormally-shaped platelets indicative of platelet dysfunction disorders. True thrombocytopenia can be caused by a myriad of conditions including systemic disease, infection, drugs, and primary hematologic disorders. The approach to thrombocytopenia is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=see_link\">",
"     \"Clinical manifestations and evaluation of thrombocytopenia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link\">",
"     \"Approach to the adult patient with thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenia or anemia may indicate underlying systemic disease (eg, malignancy, infection) or a bone marrow disorder (eg, myelodysplasia) and should be evaluated accordingly. Some medications, including antibiotics and anticonvulsants, may cause severe bone marrow injury with subsequent pancytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prothrombin time (PT) is used to assess the extrinsic pathway of clotting, which consists of tissue factor and factor VII, and coagulation factors in the common pathway (factors II [prothrombin], V, X, and fibrinogen) (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 2",
"    </a>",
"    ). The activated partial thromboplastin time (aPTT or PTT) is used to assess the integrity of the intrinsic pathway (prekallikrein, high molecular weight kininogen, factors VIII, IX, XI, XII), as well as the common pathway. Interpretation of abnormal PT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PTT and their associated causes is described in a table (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients may have false negative test results, especially with Von Willebrand disease or if the disease is mild. Patients with persistent bruising should continue to be followed and may need further testing despite negative test results initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"     \"Clinical presentation and diagnosis of von Willebrand disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H428230962\">",
"     'Follow-up and referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8756703\">",
"    <span class=\"h3\">",
"     Tests of platelet function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of platelet function can be valuable in the evaluation of easy bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/8\">",
"     8",
"    </a>",
"    ]. Recognition of impaired platelet function may be important to prevent excessive bruising and bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link\">",
"     \"Congenital and acquired disorders of platelet function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bleeding time measures the amount of time required for an incision to stop bleeding. The clinical usefulness of the test, however, is questionable. Bleeding times have been shown to be poorly reproducible and insensitive, and results are subject to numerous factors not related to platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. We therefore do not feel that the bleeding time has clinical utility as a part of an evaluation for easy bruising. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Platelet Function Analyzer (PFA-100), a simple and rapid measure of platelet function, may be more sensitive and reproducible than the bleeding time for diagnosing platelet function abnormalities. Results are expressed in terms of a normal or elevated (abnormal) &ldquo;closure time.&rdquo; Elevated closure times suggest the possibility of a qualitative platelet function defect. Unlike the bleeding time, the PFA-100 allows one to detect",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"      aspirin",
"     </a>",
"     /NSAID",
"    </span>",
"    induced platelet dysfunction, which is commonly implicated in patients with an increased bruising tendency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9784/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a normal PFA-100 does not rule out inherited or acquired platelet disorders. The PFA-100 and other tests of platelet function are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H17#H17\">",
"     \"Platelet function testing\", section on 'The platelet function analyzer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8756696\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixing studies and factor assays determine if the patient has a clotting factor deficiency or a factor inhibitor. These tests are done when initial workup with PT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PTT testing is abnormal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional testing for renal, hepatic, endocrine, or immune dysfunction is indicated only if other signs or symptoms indicate underlying disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428230962\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AND REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reassurance is appropriate for patients with bruising mainly on the lower extremities, no other evidence of bleeding, and no personal or family history of significant bleeding. These patients should be followed up within a few months.",
"   </p>",
"   <p>",
"    For patients with recent medication exposure known to cause bruising or bleeding (",
"    <a class=\"graphic graphic_table graphicRef73534 \" href=\"UTD.htm?35/39/36477\">",
"     table 2",
"    </a>",
"    ), the clinician should discontinue the culprit medication if possible. After allowing for drug washout and bruise healing (approximately two to four weeks), the clinician should re-examine the patient for evidence of new bruises.",
"   </p>",
"   <p>",
"    Patients with atypical bruising over the face, trunk, or back should be evaluated for physical abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link&amp;anchor=H4#H4\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link&amp;anchor=H8920150#H8920150\">",
"     \"Intimate partner violence: Diagnosis and screening\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link&amp;anchor=H18#H18\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\", section on 'Screening and assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with any of the following should be referred to a hematologist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continued significant bruising (five or more bruises greater than 1 cm in diameter) without any known trauma",
"     </li>",
"     <li>",
"      Personal or family history of abnormal bleeding, especially after surgeries or injuries",
"     </li>",
"     <li>",
"      Associated bleeding from other sites (eg, recurrent epistaxis, gingival bleeding, hemarthrosis)",
"     </li>",
"     <li>",
"      Abnormal laboratory tests that suggest a bleeding diathesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428230970\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of bruising can be broadly classified into disorders of blood vessels and surrounding tissue, platelet abnormalities, and coagulation disorders (",
"      <a class=\"graphic graphic_table graphicRef67597 \" href=\"UTD.htm?1/47/1790\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H428230883\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history and physical examination are more useful than laboratory testing in the evaluation of easy bruising. The patient should be asked about associated trauma, location and severity of bruising, bleeding history with previous procedures, medication use, nutrition, and family history. (See",
"      <a class=\"local\" href=\"#H7213118\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The appearance of bruising may assist with diagnosis of the underlying etiology. Bruises should be distinguished from petechiae and purpura, which may also occur with bruising. The presence of other examination findings such as lymphadenopathy or hepatosplenomegaly may also help narrow the diagnosis. (See",
"      <a class=\"local\" href=\"#H7213160\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation for bruising should be considered an adjunct to performing a good history and physical examination. No immediate workup is necessary in patients who meet the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Distribution of bruising mainly along distal extremities",
"     </li>",
"     <li>",
"      No other evidence of bleeding (eg, recurrent epistaxis, gingival bleeding, hemarthrosis), and",
"     </li>",
"     <li>",
"      No personal or family history of significant bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients can be reassured that there are no concerning findings at this time. They should be followed up in a few months and told to return if symptoms persist or worsen. In all others, baseline assays including a complete blood count (CBC) with differential and platelet count, prothrombin time (PT), and activated partial thromboplastin time (PTT) should be performed as initial testing. (See",
"    <a class=\"local\" href=\"#H7213167\">",
"     'Laboratory testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with any of the following should be referred to a hematologist (see",
"      <a class=\"local\" href=\"#H428230962\">",
"       'Follow-up and referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continued significant bruising (five or more bruises greater than 1 cm in diameter) without any known trauma",
"     </li>",
"     <li>",
"      Personal or family history of abnormal bleeding after surgeries or trauma",
"     </li>",
"     <li>",
"      Associated bleeding from other sites (eg, recurrent epistaxis, gingival bleeding, hemarthrosis)",
"     </li>",
"     <li>",
"      Abnormal laboratory tests that suggest a bleeding diathesis",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/1\">",
"      Mauer AC, Khazanov NA, Levenkova N, et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/2\">",
"      Wahlberg T, Blomb&auml;ck M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf Med 1980; 19:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/3\">",
"      Sr&aacute;mek A, Eikenboom JC, Bri&euml;t E, et al. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/4\">",
"      Garvey B. Easy bruising in women. Can Fam Physician 1984; 30:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/5\">",
"      Valente MJ, Abramson N. Easy bruisability. South Med J 2006; 99:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/6\">",
"      Rodeghiero F, Tosetto A, Abshire T, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/7\">",
"      Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/8\">",
"      Hayward CP. Diagnostic evaluation of platelet function disorders. Blood Rev 2011; 25:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/9\">",
"      Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/10\">",
"      Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9784/abstract/11\">",
"      Lippi G, Manzato F, Franchini M, et al. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics. Clin Exp Med 2001; 1:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16287 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-02329B04FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9784=[""].join("\n");
var outline_f9_35_9784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H428230970\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7213103\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428230978\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7213111\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428230883\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428230906\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7213118\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2061949\">",
"      - Associated trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2062026\">",
"      - Location and severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7213125\">",
"      - Bleeding history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7213139\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7213146\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7213153\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7213160\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8756663\">",
"      - Appearance and distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2062151\">",
"      - Other forms of bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2062246\">",
"      - Other examination findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7213167\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18063522\">",
"      - CBC, PT, and PTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8756703\">",
"      - Tests of platelet function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8756696\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428230962\">",
"      FOLLOW-UP AND REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428230970\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16287\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16287|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/20/12610\" title=\"figure 1\">",
"      Tissue factor and coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24558\" title=\"figure 2\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16287|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/32/37376\" title=\"picture 1\">",
"      Osler Weber Rendu",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/62/15330\" title=\"picture 2\">",
"      Petechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42721\" title=\"picture 3\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/62/40943\" title=\"picture 4\">",
"      Actinic purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16287|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/47/1790\" title=\"table 1\">",
"      Etiology of easy bruising",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/39/36477\" title=\"table 2\">",
"      Medications associated with easy bruising",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 3\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 4\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=related_link\">",
"      Clinical manifestations and evaluation of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=related_link\">",
"      Elder mistreatment: Abuse, neglect, and financial exploitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26841?source=related_link\">",
"      Evaluation of purpura in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=related_link\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=related_link\">",
"      Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15048?source=related_link\">",
"      Psychogenic purpura (Gardner-Diamond syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_35_9785="Latex allergy: Epidemiology, clinical manifestations, and diagnosis";
var content_f9_35_9785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9785/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9785/contributors\">",
"     Robert G Hamilton, PhD, DABMLI, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9785/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9785/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/35/9785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubber (polyisoprene) is a vital natural resource that is used in the manufacturing of a wide variety of commercial products ranging from airplane tires to protective medical gloves. Ninety-nine percent of natural rubber comes from one source: the sap-like fluid (latex) from the commercial rubber tree, Hevea brasiliensis (Hev b), found in Africa and Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A tube-like network of laticifer cells beneath the H. brasiliensis tree bark contain natural rubber (cis-polyisoprene), water, and cytoplasmic organelles. In addition, the cytoplasm contains a variety of enzymes and structural proteins that are involved in biosynthesis of polyisoprene, coagulation of latex, and plant defense against microbes. A number of these proteins are known to be potent allergens that elicit human IgE antibody, leading to sensitization in exposed individuals and a spectrum of allergic reactions upon subsequent exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic gives an overview of latex processing and latex allergens, and discusses the epidemiology, clinical manifestations, and diagnosis of latex allergy. The management of latex allergy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=see_link\">",
"     \"Latex allergy: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEVEA LATEX ALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are 14 known Hevea latex allergens, Hev b 1 through Hev b 14. These allergenic proteins are described in the table (",
"    <a class=\"graphic graphic_table graphicRef71927 \" href=\"UTD.htm?10/2/10285\">",
"     table 1",
"    </a>",
"    ), including their molecular weight, plant family, and any known cross-reactivity to structurally similar food, pollen, and mold allergens. The 14 allergenic Hevea proteins are involved in a broad range of activities in the rubber tree, including rubber biosynthesis, disease resistance, structure, and housekeeping.",
"   </p>",
"   <p>",
"    Hev b 1, 2, 3, 4, 5, 6.02, 7.01 and 13 have been identified as the most highly sensitizing of the Hevea allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. There is disagreement as to the relative clinical importance of certain Hevea allergens, such as Hev b 2 and Hev b 13. However, this discussion is largely academic because management of an individual with latex allergy involves avoidance of exposure to all Hev b allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hevea indicator allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four Hevea proteins are particularly useful as \"indicator\" allergens for assessment of the allergen content of rubber products or as markers of the presence of latex in the environment (",
"    <a class=\"graphic graphic_table graphicRef71927 \" href=\"UTD.htm?10/2/10285\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hev b 1 (rubber elongation factor) and Hev b 3 (prenyltransferase) are associated with the polyisoprene rubber particle. These two allergens most commonly induce IgE antibody responses in individuals who become sensitized through direct mucosal exposure to Hevea rubber products.",
"     </li>",
"     <li>",
"      Hev b 5 (acidic protein) and Hev b 6.02 (mature hevein) are soluble allergens that are present in the latex cytosol or C-serum. These proteins are released from dipped rubber products, mainly latex gloves, and transported via aerosolized powder used for glove donning, or sloughed directly into the environment. Exposure to these allergens through direct contact or inhalation occurs most frequently in occupations in which protective rubber gloves are frequently worn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cross-sensitization between latex, fruit, and pollen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical associations exist between latex allergy and allergic responses to a number of fruits and vegetables, such as banana, kiwi, avocado, chestnut, papaya, potato, and tomato, and goldenrod pollen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The Hev b allergens that have structural homology with selected proteins in these plant foods are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71927 \" href=\"UTD.htm?10/2/10285\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The major pan-allergen responsible for much of the fruit-latex cross-reactivity is a defense-related protein (class 1 chitinase) that displays structural homology to Hev b 6.01 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Hev b 5 possesses homology with an acidic protein in kiwi fruit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/16\">",
"     16",
"    </a>",
"    ]. Hev b 6.02 (mature hevein) shares structural homology with wheat germ agglutinin and endochitinases in avocado and banana [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. The Hev b 7 homologues (Hev b 7.01 and Hev b 7.02) are esterases that share structural homology with patatin (Sol t 1), the major storage protein in potato tubers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Latex-fruit syndrome is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEVEA LATEX PROCESSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hevea latex can be separated by centrifugation into three discrete layers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. The top layer contains particles of natural rubber. The middle fraction or C-serum contains soluble proteins, including plant enzymes. C-serum proteins are used in preparing skin test extracts. The lower layer contains the lutoid pellet, which is composed of luciferous organelles that contain hevamines with chitinase and lysozyme activity and hevein, a fungitoxic protein. The upper layer is used to manufacture solid rubber products and the middle and lower fractions are used to manufacture dipped rubber products.",
"   </p>",
"   <p>",
"    The milky fluid or latex from the rubber tree is processed by one of two pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 90 percent of Hevea latex is acid coagulated into dry sheets or crumbled particles and used to manufacture molded rubber products (eg, pneumatic tires for vehicles, catheters, syringe plungers, vial stoppers, and shoe soles). This processing involves prolonged treatment at high temperatures, which decreases allergenicity. Solid rubber products contain low levels of latex allergens, mainly Hev b 1 and Hev b 3.",
"     </li>",
"     <li>",
"      The remaining 10 percent of Hevea latex is ammoniated to prevent bacterial growth. A variety of low molecular weight chemical additives (eg, anti-oxidants, accelerators, preservatives) are often used in the process. Ammoniated latex is used to manufacture dipped rubber products on porcelain molds (eg, medical gloves, condoms, catheters, and toy balloons). Dipped rubber products contain higher levels of latex allergens, including Hev b 5, Hev b 6, and Hev b 13. The majority of allergic reactions to Hevea latex proteins result from exposure to dipped rubber products.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical Hevea latex gloves can be categorized by their application and degree of sterilization (non-sterile examination gloves, and sterile procedure and surgeon gloves) and by the presence or absence of donning powder (powdered versus powder-free). Allergenic protein that adheres to cornstarch donning powder readily distributes into the environment following powdered glove use. Allergic airway symptoms can result from the aerosolized latex allergen, but rarely from the cornstarch powder itself. Powder-free latex gloves generally contain the lowest levels of allergens as a result of a final chlorination wash process. Avoidance of powdered latex products is the most efficient means of reducing Hevea latex allergen exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of latex",
"    <span class=\"nowrap\">",
"     sensitization/allergy",
"    </span>",
"    skyrocketed in the mid to late 1990s, due to a significant increase in the use of latex gloves by clinicians and other healthcare employees (physicians, nurses, dentists, laboratory workers, housekeepers, emergency medical technicians, patient transporters) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent widespread avoidance of powdered latex gloves in many hospitals resulted in a marked decrease in the number of new cases of latex allergy among healthcare workers and patients receiving multiple surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/23\">",
"     23",
"    </a>",
"    ]. However, latex allergy continues to be a serious issue in countries where powdered latex gloves are still widely used by medical personnel, patient groups (eg dialysis patients), and in select occupations (eg, florists, food handlers) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/24-30\">",
"     24-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Latex allergy epidemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors contributed to the epidemic of latex allergy in North America and Europe. In 1992, the United States Occupational Safety and Health Administration (OSHA) issued the Bloodborne Pathogens Standard that required protective glove use. The introduction of \"universal precautions\" increased the use of medical gloves. This increased demand for natural rubber latex came at a time when the supply of latex was limited. Thus, latex was collected from increasingly younger trees that had been treated with stimulants to produce higher levels of latex per tree.",
"   </p>",
"   <p>",
"    Both tapping of younger trees and the use of stimulant chemicals increased the level of allergenic proteins in the collected latex. The latex was processed without the customary delay when it arrived at the manufacturing facility, rather than being stored for extended periods. This rapid turnover of latex minimized the extent of protein denaturation that naturally occurs during storage at high pH caused by the presence of ammonia. Together, these factors increased the amount of allergenic protein in the raw material and ultimately in the finished latex medical gloves. Higher levels of protein exacerbated the problem of latex allergy among the medical and dental communities by increasing H. brasiliensis allergen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevalence in the general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence estimates of sensitization to latex allergens are highly dependent upon the population studied and the techniques and reagents used to identify cases (questionnaire, IgE antibody skin",
"    <span class=\"nowrap\">",
"     testing/serology",
"    </span>",
"    evaluation) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/33\">",
"     33",
"    </a>",
"    ]. As an example, diagnostic procedures using skin test or serology reagents will be biased toward detecting individuals sensitized to Hev b 6.02, because this protein is the most abundant allergen in latex extracts.",
"   </p>",
"   <p>",
"    Hevea latex sensitization (IgE antibody positivity) among the general population was estimated at 3 to 9.5 percent in the mid 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The prevalence of latex sensitization in the general population fell to &lt;1 percent by 2006 in countries where Hevea latex avoidance was promoted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/33\">",
"     33",
"    </a>",
"    ]. Rates of clinical IgE-mediated allergy are even lower. However, these numbers do not include individuals with allergic contact dermatitis to latex, a reaction that is not IgE-mediated (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Clinical manifestations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevalence in the healthcare community",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant numbers of cases of Hevea latex allergy were identified in the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/37\">",
"     37",
"    </a>",
"    ]. By 1991, latex allergy was such a serious health issue that the United States Food and Drug Administration convened an international symposium on latex allergy. Increased occupational exposure to Hevea allergens occurred principally among the medical and dental communities. Use of latex gloves resulted in both direct cutaneous contact with Hevea allergens and inhalation of aerosolized Hevea allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Latex allergy achieved epidemic proportions in the medical community by the mid 1990s. An estimated prevalence of sensitization among the general healthcare worker population in one study was 12.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/40\">",
"     40",
"    </a>",
"    ]. A similar prevalence of sensitization to Hevea allergens of 10.7 percent was reported for routinely exposed operating room nurses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/41\">",
"     41",
"    </a>",
"    ]. Rates fell to approximately 4 percent with the introduction of powder-free gloves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/29,42\">",
"     29,42",
"    </a>",
"    ]. It can be assumed that rates have decreased even further with the increased use of non-latex gloves. However, new cases of latex allergy continue as a result of inadvertent exposures from high levels of Hevea allergen in less obvious sources, such as toy balloons and dental dams [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevalence in patients receiving multiple surgeries",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second high risk group involved individuals who were frequently exposed to latex as a result of multiple surgeries, especially abdominal or genitourinary surgery. The most high profile group was children with spina bifida who were sensitized through direct mucosal exposure to Hevea rubber products as a result of multiple surgeries early in life and frequent bladder catheterization and manual rectal disimpaction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. It has been estimated that between one third and two thirds of children who underwent their surgeries in the 1990s became sensitized to Hevea allergens (developed IgE antibodies to latex allergens). A significant proportion manifested latex-induced allergic reactions upon subsequent exposure to latex gloves or urinary catheters. The rate of latex sensitization and allergy has decreased significantly in children with spina bifida since the implementation of latex avoidance compared with historical controls (55 versus 5 percent for sensitization and 37 versus 0.8 percent for allergy, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main risk factors for latex allergy are occupational exposure and an atopic tendency. Rates of latex allergy are higher in patients sensitized to other allergens and those with eczema or fruit and vegetable allergy.",
"   </p>",
"   <p>",
"    Occupations in which latex gloves are commonly used include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Healthcare workers",
"     </li>",
"     <li>",
"      Food",
"      <span class=\"nowrap\">",
"       handlers/restaurant",
"      </span>",
"      workers",
"     </li>",
"     <li>",
"      Domestic workers",
"     </li>",
"     <li>",
"      Hairdressers",
"     </li>",
"     <li>",
"      Security personnel",
"     </li>",
"     <li>",
"      Construction workers",
"     </li>",
"     <li>",
"      Greenhouse",
"      <span class=\"nowrap\">",
"       workers/gardeners",
"      </span>",
"     </li>",
"     <li>",
"      Painters",
"     </li>",
"     <li>",
"      Funeral home workers",
"     </li>",
"     <li>",
"      First-responders such as police officers, firefighters, and ambulance attendants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Health care workers with latex allergy are more likely to have interleukin-13 (IL-13) and IL-18 promoter polymorphisms than nonatopic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/48\">",
"     48",
"    </a>",
"    ]. However, these polymorphisms do not occur with increased frequency in patients with spina bifida or bladder exstrophy and concomitant latex allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/49\">",
"     49",
"    </a>",
"    ]. Risk factors in these patients include the number of prior operations and history of atopic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms manifested during a latex-induced reaction depend upon the route of exposure, the amount of allergen in the natural rubber product, and the underlying mechanism of the reaction (irritant, non-IgE mediated, or IgE-mediated) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common complaint of individuals who wear Hevea latex medical gloves is of dry, crusted, and irritated skin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/51\">",
"     51",
"    </a>",
"    ]. Erythema and vesicle formation are common. This rash is similar in appearance to allergic contact dermatitis, but delayed-type hypersensitivity cannot be demonstrated to traces of additive chemicals in the gloves. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Allergic contact dermatitis'",
"    </a>",
"    below.) Rather, this rash is an irritant contact dermatitis. It is induced by a combination of factors: sweating associated with occlusion by the glove, prolonged contact with an alkaline pH due to cornstarch now used in many powdered gloves, frequent hand washing, and the use of caustic hand sanitizers and detergents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allergic contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic contact dermatitis presents as skin rash and itching one to four days after direct skin contact with a rubber latex product. The initial appearance of the rash is frequently an acute eczematous dermatitis, often with vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/52\">",
"     52",
"    </a>",
"    ]. The rash takes on a more dry, crusted, lichenified appearance with continued latex exposure (",
"    <a class=\"graphic graphic_picture graphicRef51951 \" href=\"UTD.htm?26/46/27362\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This reaction is a T cell-mediated delayed-type hypersensitivity (type IVc) to a number of the additive oxidant and accelerator chemicals (thiurams, carbamates, benzothiazoles, thiourea, amines) that are used in the latex manufacturing process [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/51,53\">",
"     51,53",
"    </a>",
"    ]. It is not a reaction to Hev b allergens.",
"   </p>",
"   <p>",
"    Breaches in the skin barrier secondary to contact dermatitis may increase the risk of IgE-mediated latex sensitization because of increased absorption of allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Allergic contact urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated immediate-type hypersensitivity (type 1) is manifested as contact urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/3,54\">",
"     3,54",
"    </a>",
"    ]. Contact urticaria is the most common allergic reaction reported by healthcare workers who use latex medical gloves.",
"   </p>",
"   <p>",
"    Redness, itching, and wheal and flare reactions occur at the site of rubber-skin contact within 10 to 15 minutes. The acute reaction can be followed by a delayed-type allergic contact dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/38,55\">",
"     38,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Allergic contact dermatitis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rhinoconjunctivitis and asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manipulation of powdered latex gloves produces an aerosol of Hevea allergens that can trigger rhinitis and asthma symptoms in latex sensitive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/39,50,56,57\">",
"     39,50,56,57",
"    </a>",
"    ]. Latex-induced sneezing, ocular tearing and itching, nasal congestion, and rhinorrhea are indistinguishable from symptoms of acute seasonal pollenosis. Therefore, recognizing the temporal relationship between symptoms and latex exposure is critical.",
"   </p>",
"   <p>",
"    Preexisting asthma is not a prerequisite for the development of latex-related asthma. The upper and lower airway allergic symptoms can be so severe that some occupationally-exposed workers must leave their place of employment unless the institution can eliminate or sufficiently decrease exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/34,50\">",
"     34,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions have occurred after use of various latex-based products in both medical and nonmedical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/52,58-62\">",
"     52,58-62",
"    </a>",
"    ]. The most common products that have caused anaphylaxis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gloves",
"     </li>",
"     <li>",
"      Balloon tipped catheters (eg, used during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema examination, arterial catheterization)",
"     </li>",
"     <li>",
"      Dental cofferdams",
"     </li>",
"     <li>",
"      Condoms",
"     </li>",
"     <li>",
"      Adhesives for hair extensions",
"     </li>",
"     <li>",
"      Toy balloons",
"     </li>",
"     <li>",
"      Pacifiers, teethers, bottle nipples",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/442?source=see_link\">",
"     \"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the presence of latex allergy can be challenging. The most reliable indicator of allergy is a strong clinical history, associating exposure and symptoms. Confirmatory tests (skin tests, serology, and provocation) are limited by reagent availability, varying reagent",
"    <span class=\"nowrap\">",
"     sensitivity/specificity",
"    </span>",
"    and composition, and significant potential risks for triggering serious reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of latex allergy begins with a clinical history of allergic reactions that are temporally associated with exposure to Hevea latex-containing products (",
"    <a class=\"graphic graphic_table graphicRef63643 \" href=\"UTD.htm?13/12/13518\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/45,63\">",
"     45,63",
"    </a>",
"    ]. Associated risk factors include hand dermatitis,",
"    <span class=\"nowrap\">",
"     fruit/vegetable",
"    </span>",
"    allergy, and atopy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk factors'",
"    </a>",
"    above.) Once there is a high clinical suspicion of latex allergy, the next step is testing to try to confirm sensitization (IgE antibody positivity) to Hevea allergens by skin testing or detection of Hevea specific IgE in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Patch testing can be used to distinguish dermatitis caused by cell-mediated delayed type hypersensitivity reactions to Hevea brasiliensis latex components [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/66\">",
"     66",
"    </a>",
"    ] and chemicals added to rubber [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/67\">",
"     67",
"    </a>",
"    ] from immediate type hypersensitivity responses elicited by IgE antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing with extracts prepared from latex C-serum is a safe and effective diagnostic procedure when extracts are standardized in terms of their allergen content and stability [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/9,64,68\">",
"     9,64,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Prick/puncture",
"    </span>",
"    skin testing with extracts of Hevea latex is widely performed in Europe and Canada, where at least three commercial H. brasiliensis extracts are available in a glycerinated form [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/68\">",
"     68",
"    </a>",
"    ]. Commercially available skin test extracts are prepared using sterile filtered C-serum from either non-ammoniated or ammoniated Hevea latex, which is then glycerinated to increase its shelf-life. The C-serum contains both soluble and lutoid allergens that are released from the rubber particles. The non-ammoniated form of C-serum used in the skin test reagents in Europe is remarkably comprehensive in its allergen composition.",
"   </p>",
"   <p>",
"    The skin test procedure involves performing a puncture with one of several lancet devices through a drop of latex extract at sequential concentrations ranging from 0.001 to 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of protein. The results are read after 15 minutes and compared with the positive histamine and negative saline controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of skin testing for allergic disease\", section on 'Prick/puncture method'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity ranged from 65 to 96 percent and specificity from 88 to 94 percent for use of the available extract products in pediatric patients with a history of urticaria, rhinoconjunctivitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asthma suspected to be triggered by natural rubber latex allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no commercial skin test reagent available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/64\">",
"     64",
"    </a>",
"    ]. This has forced allergists in the United States who want to attempt skin testing to create extracts prepared in the office from Hevea latex products that vary widely in their allergen content [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Extracts prepared from examination gloves are unstable, uncharacterized, and of highly variable potency. The inability to document the presence and content of Hevea allergens in office-prepared extracts has led to concerns about false negative diagnostic skin test results. Another concern is the potential for systemic reactions occurring as a result of skin testing with non-standardized Hevea extracts, due to potentially high levels of Hevea allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/45\">",
"     45",
"    </a>",
"    ]. For these reasons, use of these preparations is discouraged.",
"   </p>",
"   <p>",
"    Puncturing through a Hevea containing product (powdered glove) as an alternative or secondary testing method is also not encouraged, since it is not possible to know how much allergen has been distributed into the skin. There is a risk of a systemic allergic reaction from high dose exposure or inadvertent inhalation with this testing method [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/45,69\">",
"     45,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serology testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preferred alternative to a",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    skin test for confirming sensitization when commercial skin test reagents are not available is the measurement of Hevea latex-specific IgE antibody in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/45,63,65,69,73\">",
"     45,63,65,69,73",
"    </a>",
"    ]. Two serologic methods are widely used throughout the world: the Phadia ImmunoCAP and the Siemens Immulite autoanalyzer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. These assays involve incubation of test human serum with a Hevea latex allergen-containing reagent. Bound IgE antibody is detected with an enzyme-labeled anti-human IgE reagent. Results are interpolated from a total IgE calibration curve in",
"    <span class=\"nowrap\">",
"     kUa/L.",
"    </span>",
"    The nominal reported analytic sensitivity of these assays is 0.1",
"    <span class=\"nowrap\">",
"     kUa/L",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    The ImmunoCAP and Immulite assays display a diagnostic sensitivity and specificity of approximately 80 percent and &gt;95 percent, respectively, when compared to the puncture skin test (lower detectable limit of these serologic assays at the time of this study was 0.35",
"    <span class=\"nowrap\">",
"     kUa/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A chip-based microarray containing eight recombinant Hev b allergens was shown to more clearly define the specificity of IgE anti-latex with no loss in diagnostic sensitivity compared with the singleplex ImmunoCAP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/76\">",
"     76",
"    </a>",
"    ] A commercial version of this chip microarray (ImmunoCAP-ISAC) that contains recombinant Hev b1, 3, 5, 6, and 8 is under investigation. Results from one study suggest that this technique can distinguish between patients with latex allergy and sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Provocation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about the safety, reproducibility, and interpretation of provocation methods have kept these in the category of last resort testing when all other tests are negative, but the patient's history strongly suggests latex sensitization. A variety of glove use, nasal provocation, and inhalation challenge procedures have been reported. Latex induced skin reactions or upper and lower airway allergic symptoms are used as the provocation tests' endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9785/abstract/5,39,78-82\">",
"     5,39,78-82",
"    </a>",
"    ]. Most of these methods have remained research procedures that are not suitable for routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Testing recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the available option for diagnostic testing with FDA-cleared reagents is latex-specific IgE antibody serology with the ImmunoCAP or Immulite system. In other parts of the world, where a characterized skin test reagent is available,",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    skin test can be performed first. This may be followed by a latex-specific IgE antibody serology with one of the assay methods if the skin test data remain inconsistent with the history-driven diagnosis. Provocation testing is generally not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are 14 known Hevea latex allergens, Hev b 1 through Hev b 14. Four Hevea proteins are particularly useful as \"indicator\" allergens for assessment of the allergen content of rubber products or as markers of the presence of latex in the environment: Hev b 1, 3, 5, and 6.02. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hevea latex allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical associations exist between latex allergy and allergic responses to a number of fruits and vegetables, including banana, kiwi, avocado, chestnut, papaya, potato, and tomato, because of cross-reactivity between various proteins. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cross-sensitization between latex, fruit, and pollen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of latex allergy peaked in the 1990s in many countries, due to the introduction of \"universal precautions\". Rates in the general population and high risk populations have decreased since then with the use of powder-free latex gloves and latex alternatives. However, rates of latex glove use, and associated latex allergy, remain high in some countries and in certain occupations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complaint of individuals who wear Hevea latex medical gloves is of dry, crusted, and irritated skin. This does not represent an allergic reaction, but rather is an irritant contact dermatitis. Clinical manifestations of latex allergy include non-IgE mediated allergic contact dermatitis and IgE-mediated urticaria, rhinoconjunctivitis, asthma, and anaphylaxis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establishing the presence of latex allergy can be challenging. The most reliable indicator of allergy is a strong clinical history that associates exposure with symptoms. Confirmatory tests (skin tests, serology, and provocation) are limited by reagent availability, varying reagent",
"      <span class=\"nowrap\">",
"       sensitivity/specificity",
"      </span>",
"      and composition, and significant risks for triggering serious reactions. In the United States, serology is the test of choice. In other parts of the world, where a characterized skin test reagent is available,",
"      <span class=\"nowrap\">",
"       prick/puncture",
"      </span>",
"      skin test can be performed first. Provocation testing is generally not recommended. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/1\">",
"      Jacob JL, d'Auzac J, Prev&ocirc;t JC. The composition of natural latex from Hevea brasiliensis. Clin Rev Allergy 1993; 11:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/2\">",
"      Alenius H, Kurup V, Kelly K, et al. Latex allergy: frequent occurrence of IgE antibodies to a cluster of 11 latex proteins in patients with spina bifida and histories of anaphylaxis. J Lab Clin Med 1994; 123:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/3\">",
"      Breiteneder H, Scheiner O. Molecular and immunological characteristics of latex allergens. Int Arch Allergy Immunol 1998; 116:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/4\">",
"      Sussman GL, Beezhold DH, Liss G. Latex allergy: historical perspective. Methods 2002; 27:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/5\">",
"      Jaeger D, Kleinhans D, Czuppon AB, Baur X. Latex-specific proteins causing immediate-type cutaneous, nasal, bronchial, and systemic reactions. J Allergy Clin Immunol 1992; 89:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/6\">",
"      Beezhold D, Beck WC. Surgical glove powders bind latex antigens. Arch Surg 1992; 127:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/7\">",
"      Palosuo T, Lehto M, Kotovuori A, et al. Latex allergy: low prevalence of immunoglobulin E to highly purified proteins Hev b 2 and Hev b 13. Clin Exp Allergy 2007; 37:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/8\">",
"      Raulf-Heimsoth M, Rihs HP, Rozynek P, et al. Quantitative analysis of immunoglobulin E reactivity profiles in patients allergic or sensitized to natural rubber latex (Hevea brasiliensis). Clin Exp Allergy 2007; 37:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/9\">",
"      Smith AM, Amin HS, Biagini RE, et al. Percutaneous reactivity to natural rubber latex proteins persists in health-care workers following avoidance of natural rubber latex. Clin Exp Allergy 2007; 37:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/10\">",
"      Palosuo T, Alenius H, Turjanmaa K. Quantitation of latex allergens. Methods 2002; 27:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/11\">",
"      Beezhold DH, Sussman GL, Liss GM, Chang NS. Latex allergy can induce clinical reactions to specific foods. Clin Exp Allergy 1996; 26:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/12\">",
"      Bains SN, Hamilton RG, Abouhassan S, et al. Identification of clinically relevant cross-sensitization between Soliadgo virgaurea (goldenrod) and Hevea brasiliensis (natural rubber latex). J Investig Allergol Clin Immunol 2010; 20:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/13\">",
"      Mikkola JH, Alenius H, Kalkkinen N, et al. Hevein-like protein domains as a possible cause for allergen cross-reactivity between latex and banana. J Allergy Clin Immunol 1998; 102:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/14\">",
"      Blanco C, Diaz-Perales A, Collada C, et al. Class I chitinases as potential panallergens involved in the latex-fruit syndrome. J Allergy Clin Immunol 1999; 103:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/15\">",
"      Posch A, Wheeler CH, Chen Z, et al. Class I endochitinase containing a hevein domain is the causative allergen in latex-associated avocado allergy. Clin Exp Allergy 1999; 29:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/16\">",
"      Slater JE, Vedvick T, Arthur-Smith A, et al. Identification, cloning, and sequence of a major allergen (Hev b 5) from natural rubber latex (Hevea brasiliensis). J Biol Chem 1996; 271:25394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/17\">",
"      Wright HT, Brooks DM, Wright CS. Evolution of the multi-domain protein wheat germ agglutinin. J Mol Evol 1985; 21:28091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/18\">",
"      Chen Z, Posch A, Cremer R, et al. Identification of hevein (Hev b 6.02) in Hevea latex as a major cross-reacting allergen with avocado fruit in patients with latex allergy. J Allergy Clin Immunol 1998; 102:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/19\">",
"      Sowka S, Wagner S, Krebitz M, et al. cDNA cloning of the 43-kDa latex allergen Hev b 7 with sequence similarity to patatins and its expression in the yeast Pichia pastoris. Eur J Biochem 1998; 255:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/20\">",
"      Kekwick RG. The modification of polypeptides in Hevea brasiliensis latex resulting from storage and processing. Clin Rev Allergy 1993; 11:339.",
"     </a>",
"    </li>",
"    <li>",
"     Archer BL, Barnard D, Cockbain EG, et al. Structure, composition and biochemistry of Hevea latex. In: The chemistry and physics of rubber-like substances, Bateman L (Ed), John Wiley &amp; Sons, New York 1963. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/22\">",
"      Rolland JM, O'Hehir RE. Latex allergy: a model for therapy. Clin Exp Allergy 2008; 38:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/23\">",
"      Vandenplas O, Larbanois A, Vanassche F, et al. Latex-induced occupational asthma: time trend in incidence and relationship with hospital glove policies. Allergy 2009; 64:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/24\">",
"      Erkekol FO, Celik GE, Hayran M, et al. The prevalence of latex allergy in sixth-year medical students: assessment of knowledge, risk, and attitudes about future specialty direction. Ann Allergy Asthma Immunol 2008; 100:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/25\">",
"      Crippa M, Balbiani L, Baruffini A, et al. [Consensus Document. Update on latex exposure and use of gloves in Italian health care settings]. Med Lav 2008; 99:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/26\">",
"      Lopata AL, Adams S, Kirstein F, et al. Occupational allergy to latex among loom tuners in a textile factory. Int Arch Allergy Immunol 2007; 144:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/27\">",
"      Fuld RA. Adverse reactions to latex occurring in an outpatient dialysis access center. Semin Dial 2008; 21:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/28\">",
"      Miri S, Pourpak Z, Zarinara A, et al. Prevalence of type I allergy to natural rubber latex and type IV allergy to latex and rubber additives in operating room staff with glove-related symptoms. Allergy Asthma Proc 2007; 28:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/29\">",
"      Bousquet J, Flahault A, Vandenplas O, et al. Natural rubber latex allergy among health care workers: a systematic review of the evidence. J Allergy Clin Immunol 2006; 118:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/30\">",
"      A&ntilde;&iacute;barro B, Seoane FJ, Perpi&aacute; MA, Carn&eacute;s J. Latex: a hidden occupational allergen. Ann Allergy Asthma Immunol 2010; 104:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/31\">",
"      Hamann CP, Kick SA. Allergies associated with medical gloves. Manufacturing issues. Dermatol Clin 1994; 12:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/32\">",
"      Truscott W, Roley L. Glove-associated reactions: addressing an increasing concern. Dermatol Nurs 1995; 7:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/33\">",
"      Mari A, Scala E, D'Ambrosio C, et al. Latex allergy within a cohort of not-at-risk subjects with respiratory symptoms: prevalence of latex sensitization and assessment of diagnostic tools. Int Arch Allergy Immunol 2007; 143:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/34\">",
"      Sussman GL, Tarlo S, Dolovich J. The spectrum of IgE-mediated responses to latex. JAMA 1991; 265:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/35\">",
"      Ownby DR, Ownby HE, McCullough J, Shafer AW. The prevalence of anti-latex IgE antibodies in 1000 volunteer blood donors. J Allergy Clin Immunol 1996; 97:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/36\">",
"      Lebenbom-Mansour MH, Oesterle JR, Ownby DR, et al. The incidence of latex sensitivity in ambulatory surgical patients: a correlation of historical factors with positive serum immunoglobin E levels. Anesth Analg 1997; 85:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/37\">",
"      Turjanmaa K. Incidence of immediate allergy to latex gloves in hospital personnel. Contact Dermatitis 1987; 17:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/38\">",
"      Charous BL, Hamilton RG, Yunginger JW. Occupational latex exposure: characteristics of contact and systemic reactions in 47 workers. J Allergy Clin Immunol 1994; 94:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/39\">",
"      Baur X, J&auml;ger D. Airborne antigens from latex gloves. Lancet 1990; 335:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/40\">",
"      Liss GM, Sussman GL, Deal K, et al. Latex allergy: epidemiological study of 1351 hospital workers. Occup Environ Med 1997; 54:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/41\">",
"      Lagier F, Vervloet D, Lhermet I, et al. Prevalence of latex allergy in operating room nurses. J Allergy Clin Immunol 1992; 90:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/42\">",
"      Tarlo SM, Easty A, Eubanks K, et al. Outcomes of a natural rubber latex control program in an Ontario teaching hospital. J Allergy Clin Immunol 2001; 108:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/43\">",
"      Kostyal D, Horton K, Beezhold D, et al. Latex as a significant source of Hevea brasiliensis allergen exposure. Ann Allergy Asthma Immunol 2009; 103:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/44\">",
"      Slater JE. Rubber anaphylaxis. N Engl J Med 1989; 320:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/45\">",
"      Kelly KJ, Kurup V, Zacharisen M, et al. Skin and serologic testing in the diagnosis of latex allergy. J Allergy Clin Immunol 1993; 91:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/46\">",
"      Kelly KJ, Pearson ML, Kurup VP, et al. A cluster of anaphylactic reactions in children with spina bifida during general anesthesia: epidemiologic features, risk factors, and latex hypersensitivity. J Allergy Clin Immunol 1994; 94:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/47\">",
"      Blumchen K, Bayer P, Buck D, et al. Effects of latex avoidance on latex sensitization, atopy and allergic diseases in patients with spina bifida. Allergy 2010; 65:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/48\">",
"      Brown RH, Hamilton RG, Mintz M, et al. Genetic predisposition to latex allergy: role of interleukin 13 and interleukin 18. Anesthesiology 2005; 102:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/49\">",
"      Monitto CL, Hamilton RG, Levey E, et al. Genetic predisposition to natural rubber latex allergy differs between health care workers and high-risk patients. Anesth Analg 2010; 110:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/50\">",
"      Charous BL, Tarlo SM, Charous MA, Kelly K. Natural rubber latex allergy in the occupational setting. Methods 2002; 27:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/51\">",
"      Heese A, van Hintzenstern J, Peters KP, et al. Allergic and irritant reactions to rubber gloves in medical health services. Spectrum, diagnostic approach, and therapy. J Am Acad Dermatol 1991; 25:831.",
"     </a>",
"    </li>",
"    <li>",
"     Sussman, G, Gold, M. Guidelines for the management of latex allergies and safe latex use in health care facilities. Am College of Allergy Asthma and Immunology 1996. www.acaai.org/public/physicians/latex.htm (Accessed on January 16, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/53\">",
"      Pecquet C. Allergic contact dermatitis to rubber. Clinical aspects and main allergens. Clin Rev Allergy 1993; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/54\">",
"      Williams JD, Lee AY, Matheson MC, et al. Occupational contact urticaria: Australian data. Br J Dermatol 2008; 159:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/55\">",
"      Turjanmaa K, Reunala T. Contact urticaria from rubber gloves. Dermatol Clin 1988; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/56\">",
"      Seaton A, Cherrie B, Turnbull J. Rubber glove asthma. Br Med J (Clin Res Ed) 1988; 296:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/57\">",
"      Tarlo SM, Wong L, Roos J, Booth N. Occupational asthma caused by latex in a surgical glove manufacturing plant. J Allergy Clin Immunol 1990; 85:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/58\">",
"      Ownby DR, Tomlanovich M, Sammons N, McCullough J. Anaphylaxis associated with latex allergy during barium enema examinations. AJR Am J Roentgenol 1991; 156:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/59\">",
"      Oei HD, Tjiook SB, Chang KC. Anaphylaxis due to latex allergy. Allergy Proc 1992; 13:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/60\">",
"      Kimata H. Latex allergy in infants younger than 1 year. Clin Exp Allergy 2004; 34:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/61\">",
"      Cogen FC, Beezhold DH. Hair glue anaphylaxis: a hidden latex allergy. Ann Allergy Asthma Immunol 2002; 88:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/62\">",
"      Yunginger JW. Latex associated anaphylaxis. Immunol Allergy Clin North Am 2001; 21:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/63\">",
"      Hamilton RG. Diagnosis of natural rubber latex allergy. Methods 2002; 27:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/64\">",
"      Hamilton RG, Adkinson NF Jr. Natural rubber latex skin testing reagents: safety and diagnostic accuracy of nonammoniated latex, ammoniated latex, and latex rubber glove extracts. J Allergy Clin Immunol 1996; 98:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/65\">",
"      Hamilton RG, Biagini RE, Krieg EF. Diagnostic performance of Food and Drug Administration-cleared serologic assays for natural rubber latex-specific IgE antibody. The Multi-Center Latex Skin Testing Study Task Force. J Allergy Clin Immunol 1999; 103:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/66\">",
"      Bendewald MJ, Farmer SA, Davis MD. Patch testing with natural rubber latex: the Mayo Clinic experience. Dermatitis 2010; 21:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/67\">",
"      Bendewald MJ, Farmer SA, Davis MD. An 8-year retrospective review of patch testing with rubber allergens: the Mayo Clinic experience. Dermatitis 2010; 21:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/68\">",
"      Bernardini R, Pucci N, Azzari C, et al. Sensitivity and specificity of different skin prick tests with latex extracts in pediatric patients with suspected natural rubber latex allergy--a cohort study. Pediatr Allergy Immunol 2008; 19:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/69\">",
"      Hamilton RG, Adkinson NF Jr. Validation of the latex glove provocation procedure in latex-allergic subjects. Ann Allergy Asthma Immunol 1997; 79:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/70\">",
"      Yunginger JW, Jones RT, Fransway AF, et al. Extractable latex allergens and proteins in disposable medical gloves and other rubber products. J Allergy Clin Immunol 1994; 93:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/71\">",
"      Kujala V, Alenius H, Palosuo T, et al. Extractable latex allergens in airborne glove powder and in cut glove pieces. Clin Exp Allergy 2002; 32:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/72\">",
"      Yeang HY, Hamilton RG, Bernstein DI, et al. Allergen concentration in natural rubber latex. Clin Exp Allergy 2006; 36:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/73\">",
"      Biagini RE, Krieg EF, Pinkerton LE, Hamilton RG. Receiver operating characteristics analyses of Food and Drug Administration-cleared serological assays for natural rubber latex-specific immunoglobulin E antibody. Clin Diagn Lab Immunol 2001; 8:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/74\">",
"      Biagini RE, MacKenzie BA, Sammons DL, et al. Latex specific IgE: performance characteristics of the IMMULITE 2000 3gAllergy assay compared with skin testing. Ann Allergy Asthma Immunol 2006; 97:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/75\">",
"      Hamilton RG, Biagini R, Mackenzie B, et al. FDA cleared immunoassays for latex-specific IGE are missing allergenic epitopes from multiple Hev b allergens. J Allergy Clin Immunol 2002; 109:S259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/76\">",
"      Ott H, Schr&ouml;der C, Raulf-Heimsoth M, et al. Microarrays of recombinant Hevea brasiliensis proteins: a novel tool for the component-resolved diagnosis of natural rubber latex allergy. J Investig Allergol Clin Immunol 2010; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/77\">",
"      Ebo DG, Hagendorens MM, De Knop KJ, et al. Component-resolved diagnosis from latex allergy by microarray. Clin Exp Allergy 2010; 40:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/78\">",
"      Kurtz KM, Hamilton RG, Adkinson NF Jr. Role and application of provocation in the diagnosis of occupational latex allergy. Ann Allergy Asthma Immunol 1999; 83:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/79\">",
"      Laoprasert N, Swanson MC, Jones RT, et al. Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions. J Allergy Clin Immunol 1998; 102:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/80\">",
"      Kurtz KM, Hamilton RG, Schaefer JA, et al. Repeated latex aeroallergen challenges employing a hooded exposure chamber: safety and reproducibility. Allergy 2001; 56:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/81\">",
"      Bernardini R, Pucci N, Rossi ME, et al. Allergen specific nasal challenge to latex in children with latex allergy: clinical and immunological evaluation. Int J Immunopathol Pharmacol 2008; 21:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9785/abstract/82\">",
"      Unsel M, Mete N, Ardeniz O, et al. The importance of nasal provocation test in the diagnosis of natural rubber latex allergy. Allergy 2009; 64:862.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5543 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9785=[""].join("\n");
var outline_f9_35_9785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEVEA LATEX ALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hevea indicator allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cross-sensitization between latex, fruit, and pollen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEVEA LATEX PROCESSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Latex allergy epidemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevalence in the general population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevalence in the healthcare community",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevalence in patients receiving multiple surgeries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Allergic contact urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rhinoconjunctivitis and asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serology testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Provocation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Testing recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/46/27362\" title=\"picture 1\">",
"      Latex allergy - allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/2/10285\" title=\"table 1\">",
"      Latex allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/12/13518\" title=\"table 2\">",
"      Latex allergy diagnostic questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5785?source=related_link\">",
"      Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/442?source=related_link\">",
"      Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_35_9786="When to initiate antiretroviral therapy in HIV-infected patients";
var content_f9_35_9786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   When to initiate antiretroviral therapy in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9786/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9786/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9786/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/35/9786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/35/9786/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/35/9786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of the introduction of potent combination antiretroviral therapy (ART) in 1996, there was a \"hit hard and hit early\" approach to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/1\">",
"     1",
"    </a>",
"    ]. However, when the toxicities and resistance of chronic ART became apparent and complicated dosing regimens thwarted adherence, the pendulum swung back to withholding therapy in patients with relatively preserved CD4 T cell counts.",
"   </p>",
"   <p>",
"    Advances in HIV therapy in the last decade have shifted the risk-benefit ratio to earlier treatment. HIV treatment guidelines from the United States Department of Health and Human Services (DHHS) and the International Antiviral Society-USA Panel now recommend antiretroviral treatment in all patients with HIV infection, regardless of CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This topic will discuss the strength of the evidence supporting these treatment guidelines.",
"   </p>",
"   <p>",
"    The selection of specific medications, patient evaluation, counseling regarding side effects, and laboratory monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of combination antiretroviral therapy are to increase disease-free survival through suppression of HIV replication and improvement in immunologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Viral suppression also decreases the risk of HIV transmission to an uninfected sexual partner [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATORS OF IMMUNE FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CD4 cell count is the main indicator of immune function in patients who are HIV-infected and is the strongest predictor of disease progression and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. It is also one of the key factors in deciding whether to initiate chemoprophylaxis for opportunistic infections and to evaluate clinical complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RATIONALE FOR TREATMENT OF ALL HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of antiretroviral therapy (ART) in decreasing morbidity and mortality in patients with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    have been well known for a long time. Previous recommendations to withhold therapy in patients with a CD4 cell count &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    were heavily influenced by reported toxicities, drug resistance, and limited treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/3\">",
"     3",
"    </a>",
"    ]. The supportive arguments for treatment of all HIV-infected patients are many, and include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/9-17\">",
"     9-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic options have expanded",
"     </li>",
"     <li>",
"      The drugs are more potent than earlier agents",
"     </li>",
"     <li>",
"      Drug toxicity has declined and drug tolerability has improved",
"     </li>",
"     <li>",
"      Simplified regimens have led to improved adherence",
"     </li>",
"     <li>",
"      Untreated HIV infection has negative consequences on other comorbidities, such as coronary artery disease, liver and kidney disease, neurologic disease, and malignancy, which may be partly mediated by inflammation and proinflammatory cytokines",
"     </li>",
"     <li>",
"      Earlier therapy appears to lead to a more robust immunologic recovery compared with deferred therapy",
"     </li>",
"     <li>",
"      Suppressive ART provides an important potential public health benefit by decreasing the risk of sexual transmission. (See",
"      <a class=\"local\" href=\"#H5769013\">",
"       'Impact of ART on HIV transmission'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arguments for delayed therapy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concerns regarding long-term toxicity and drug resistance in light of the possibility of decades of ART exposure",
"     </li>",
"     <li>",
"      The high cost of HIV care with drug regimens priced at $12,000 to",
"      <span class=\"nowrap\">",
"       $15,000/year.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768830\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF DEFERRED TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed treatment can lead to subtherapeutic responses to treatment and immunologic decline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768837\">",
"    <span class=\"h2\">",
"     Risk of virologic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;One observational cohort study in 7916 HIV-infected patients who initiated antiretroviral therapy (ART) demonstrated that the risk of virologic failure to three drug classes over a 10-year period was increased in those patients who had a baseline CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    compared with patients with CD4 cell counts &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (12 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768844\">",
"    <span class=\"h2\">",
"     Incomplete immunologic recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some researchers have advocated earlier therapeutic intervention because of concerns that immunologic recovery may not be complete if treatment is initiated late in infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 366 patients with viral suppression who were followed for more than seven years, the extent of immune recovery was strongly associated with the patient's pretreatment CD4 count [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/23\">",
"       23",
"      </a>",
"      ]. For example, while 95 percent of those with a CD4 cell count &gt;300",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were able to achieve a CD4 count &gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      over the study period, only 44 percent of those with a CD4 count of &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      achieved this same threshold.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observational data suggest that immunologic recovery is more robust if ART is initiated at higher CD4 cell counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768851\">",
"    <span class=\"h2\">",
"     Progression of immunologic decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;One large cohort study of 3631 patients who had a baseline CD4 cell count &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    found that the median time to progress to a CD4 count of &lt;350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    was 2.5 years. These data led some experts to recommend early ART for all patients since the interval of time that is spent off ART (if deferring to &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    is relatively short when compared with the eventual need for lifetime therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768904\">",
"    <span class=\"h1\">",
"     IMPACT OF ART ON RISK OF OTHER COMORBIDITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768950\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data suggest that untreated HIV infection is a risk factor for developing coronary artery disease, kidney disease, neurocognitive deficits, liver disease, and non-HIV-associated malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/15,24,25\">",
"     15,24,25",
"    </a>",
"    ]. These observations may be related to HIV-induced proinflammatory cytokines, chronic inflammation, and T-cell activation, leading to end-organ damage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/26\">",
"     26",
"    </a>",
"    ]. Although antiretroviral therapy (ART) leads to a rapid decline in most markers of immune activation, they do not normalize in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/10,27,28\">",
"     10,27,28",
"    </a>",
"    ]. These observations have led to interest in the role of ART in preventing various comorbidities that are prevalent in HIV-infected patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SMART trial, a randomized controlled study of structured antiretroviral treatment interruptions noted above, higher rates of mortality related to cancer, myocardial infarction, renal- and liver-related deaths occurred in patients who stopped ART compared with those who continued ART (ie, 65 versus 39 deaths) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/24,29,30\">",
"       24,29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"       \"Structured treatment interruptions in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an observational study of 2824 patients receiving longitudinal primary care from 1997 to 2005, receipt of ART was associated with a significantly decreased incidence of comorbidities among patients with a baseline CD4 cell count",
"      <span class=\"nowrap\">",
"       &lt;350/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      compared with no ART",
"      <sup>",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768957\">",
"    <span class=\"h2\">",
"     HIV-associated nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated nephropathy is the most common cause of kidney disease in HIV-infected patients and can occur at any CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Since the introduction of potent ART, the incidence of HIV-related end-stage renal disease has declined, and this disease is now uncommon among patients with viral suppression on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Anecdotal observations of improved renal function with HIV RNA suppression on ART among those with baseline renal insufficiency also support these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2,35-38\">",
"     2,35-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768964\">",
"    <span class=\"h2\">",
"     HIV-associated neurocognitive deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HIV-associated dementia has declined since the introduction of potent ART. In one cohort, patients with viral suppression on ART had a lower risk of HIV-associated dementia than patients with detectable plasma HIV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/39\">",
"     39",
"    </a>",
"    ]. &nbsp;Observational data also suggest that patients with HIV dementia improve clinically after the initiation of HIV therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=see_link\">",
"     \"Dementia and delirium in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768971\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large cohort studies have reported a link between CD4 count 350 to 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and uncontrolled HIV viremia and the risk of AIDS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-AIDS-defining malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. The potential effect of HIV-associated immunodeficiency is particularly striking for cancers associated with other viral infections, such as hepatitis B, hepatitis C, human papillomavirus, and Epstein-Barr virus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/40,44\">",
"     40,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, several population-based analyses suggest that the incidence of AIDS- and non-AIDS-associated malignancies has declined with the era of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768978\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markers of inflammation (eg, interleukin 6) and coagulation (eg, D-dimer) appear to strongly correlate with HIV replication and an increased risk of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/10\">",
"     10",
"    </a>",
"    ]. In the SMART study, the risk of cardiovascular events was greater in those randomly assigned to treatment interruption rather than continuous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/29\">",
"     29",
"    </a>",
"    ]. Observational data also suggest that immunosuppression may be associated with an increased risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since some antiretroviral agents are also associated with insulin resistance and cardiovascular events, careful selection of initial agents is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768985\">",
"    <span class=\"h2\">",
"     Hepatitis B infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various treatment guidelines suggest using antiviral agents with dual activity against both HIV and hepatitis B virus (HBV) in the HIV-infected patient who requires HBV therapy, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The treatment of hepatitis B in the HIV-infected patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768992\">",
"    <span class=\"h2\">",
"     Hepatitis C infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic fibrosis progression rates may be slower in dually-infected patients taking ART. The treatment of hepatitis C virus in the HIV-infected patient is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5768999\">",
"    <span class=\"h2\">",
"     Aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection is associated with immunosenescence. Studies during the early AIDS epidemic demonstrated that patients over the age of 50 have a more rapid progression to AIDS and poorer overall survival following HIV seroconversion compared with younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/48\">",
"     48",
"    </a>",
"    ]. In the era of potent ART, studies have also suggested that older patients may have delayed immune recovery.",
"   </p>",
"   <p>",
"    When therapy is initiated, patients should be carefully counseled about potential side effects, since pharmacokinetic data in this patient population are scant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5769013\">",
"    <span class=\"h1\">",
"     IMPACT OF ART ON HIV TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5769072\">",
"    <span class=\"h2\">",
"     Discordant couples",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another rationale for early antiretroviral therapy (ART) initiation is to prevent HIV transmission from an HIV-seropositive person to an HIV-seronegative sexual partner [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis was performed in 5021 heterosexual discordant couples with 461 HIV transmission events to determine the role of ART in prevention of transmission. There were no transmission events to a seronegative partner among those HIV-seropositive individuals who had achieved viral suppression on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/4\">",
"     4",
"    </a>",
"    ]. A subsequent clinical trial among 1763 HIV-serodiscordant couples (HIV Prevention Trials Network; HPTN 052) demonstrated that immediate ART initiation was associated with a 96 percent reduction in HIV transmission compared with delayed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians should explain to HIV-discordant couples that viral suppression on ART decreases the risk of HIV transmission to the HIV-seronegative partner substantially, but does not eliminate the risk, or the need for traditional preventive measures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2-4,50,51\">",
"     2-4,50,51",
"    </a>",
"    ]. The details of the HPTN trial are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5769079\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART is recommended in pregnant women by various guideline panels, regardless of CD4 cell count, to decrease rates of perinatal HIV transmission as well as to treat the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/52\">",
"     52",
"    </a>",
"    ]. The evidence for this recommendation, the timing of ART relative to stage of pregnancy, and the choice of agents that are safe in pregnancy, are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5769086\">",
"    <span class=\"h2\">",
"     Injection drug users",
"    </span>",
"    &nbsp;&mdash;&nbsp;Models suggest that a combination of ART for HIV-infected persons who inject drugs, combined with opioid substitution programs and needle exchange programs, have the potential to reduce HIV transmission to HIV-uninfected injection drug users by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3301982\">",
"    <span class=\"h1\">",
"     IMPACT OF ART ON RISK OF MORTALITY FROM OPPORTUNISTIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral therapy (ART) is also effective in reducing mortality among patients with advanced immunosuppression who present with acute opportunistic infections (OIs):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 282 patients presenting with various OIs, \"early ART\" (initiated within 14 days of presentation) led to a 50 percent reduction in AIDS-related mortality compared with \"late ART\" (initiated when OI treatment was completed) without any increase in treatment-related adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/54\">",
"       54",
"      </a>",
"      ]. A survival benefit of early ART has been shown by other groups as well [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2622983\">",
"    <span class=\"h1\">",
"     THE CLINICAL BENEFIT OF ART VARIES BY BASELINE CD4 CELL COUNT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2622990\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data have demonstrated that the introduction of potent three-drug combination regimens of antiretroviral therapy (ART) in 1996 led to remarkable declines in morbidity and mortality among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The strength of the evidence for improved survival increases as the CD4 count declines.",
"   </p>",
"   <p>",
"    The impact of the patient&rsquo;s baseline CD4 cell count on treatment outcomes was well illustrated in a collaborative study (HIV-CAUSAL Collaboration) of 62,760 treatment-naive patients in Europe and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/59\">",
"     59",
"    </a>",
"    ]. Over a mean follow-up of 3.3 years, 2039 patients died. The overall risk of mortality was reduced by approximately 50 percent among those who initiated ART compared with those who did not. However, the absolute survival benefit depended on the patient&rsquo;s level of immunocompromise before treatment. In analyses stratified by CD4 cell count, the corresponding hazard ratios for mortality for treated versus untreated patients were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      0.29 for patients with &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (95% CI 0.22-0.37)",
"     </li>",
"     <li>",
"      0.33 for 100 to 199",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (95% CI 0.25-0.44)",
"     </li>",
"     <li>",
"      0.38 for 200 to 349",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (95% CI 0.28-0.52)",
"     </li>",
"     <li>",
"      0.55 for 350 to 499",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (95% CI 0.41-0.74)",
"     </li>",
"     <li>",
"      0.77 for &gt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (95% CI 0.58-1.01)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Representative studies that support the initiation of ART within various CD4 cell count strata are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Patients with CD4 counts &le;200 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials, cohort analyses and meta-analyses have definitively shown that potent ART improves survival and reduces AIDS-related complications in patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/52,60-62\">",
"     52,60-62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial (ACTG 320) in 1156 patients with CD4 cell counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      was stopped early (at 38 weeks of follow-up) when the data safety monitoring board found that the risk of progressing to the combined end point of a new AIDS-defining event or death was significantly lower in the triple therapy arm (6 percent) compared with the dual therapy arm (11 percent) (HR 0.5; 95% CI 0.33-0.76) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=see_link\">",
"       \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patients with CD4 counts &ge;200-350 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple large observational studies and a randomized controlled trial suggest that patients with CD4 cell counts between 200 and 350",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    also benefit from ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/24,63-67\">",
"     24,63-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SMART trial of structured treatment interruption, mostly ART-experienced patients (n = 5472) with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &gt;350/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      were randomly assigned to a CD4 cell count-guided strategy of resuming therapy only when the CD4 count was",
"      <span class=\"nowrap\">",
"       &lt;250/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (the drug conservation group) versus continuous ART [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/29\">",
"       29",
"      </a>",
"      ]. The trial demonstrated that the risk of opportunistic infections and death was increased more than three-fold in patients assigned to the drug conservation arm compared with the continuous therapy arm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"       \"Structured treatment interruptions in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A large retrospective collaborative study of 22,221 patients in Europe and North America examined AIDS events within various CD4 strata during the first year of ART initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/68\">",
"       68",
"      </a>",
"      ]. The collaborators evaluated whether the incidence of AIDS events and mortality decreased during months 6 through 12 compared with the first six months of treatment. ART was associated with a significant decline in AIDS event rates in patients with &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"     </li>",
"     <li>",
"      A retrospective analysis of 18 European cohort studies pooled data on treatment-naive AIDS-free patients who started ART at various baseline CD4 cell counts [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/63\">",
"       63",
"      </a>",
"      ]. Follow-up of more than 24,000 patients demonstrated that deferring combination therapy until a CD4 count between 251 and 350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      was reached was associated with higher rates of AIDS and death compared with starting therapy within the range of 351 to 450",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      (HR 1.28, 95% CI 1.04-1.57).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patients with CD4 counts 350 to 500 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data and one controlled trial suggest that initiation of ART in patients with CD4 counts between 350 and 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    decreases AIDS-related events and improves survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/14,59,68,69\">",
"     14,59,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical benefit of ART was demonstrated in the HIV Prevention Network Trial 052, which enrolled 1763 HIV-serodiscordant couples to assess the efficacy of ART in preventing HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevention aspects of the trial are discussed above. (See",
"    <a class=\"local\" href=\"#H5769013\">",
"     'Impact of ART on HIV transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In this trial, HIV-infected treatment-na&iuml;ve partners were eligible for ART if their CD4 count was between 350 and 550",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Serodiscordant couples were randomly assigned to the &ldquo;early ART&rdquo; arm (initiation of HIV treatment at enrollment) or the &ldquo;delayed ART&rdquo; arm (initiation of HIV treatment when the CD4 count dropped below 250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or after an AIDS-related illness). Patients in the early therapy arm had a lower risk of an HIV-related clinical event than those in the delayed therapy arm over the 1.7-year period of follow-up (HR 0.59; 95% CI 0.40-0.88). The difference in the rate of clinical events was most closely associated with the incidence of extrapulmonary tuberculosis, which occurred mainly among patients from endemic areas (3 versus 17 cases in the early and delayed groups, respectively). No differences in mortality rates were seen between the arms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the observational studies that supports initiation of ART among patients within the 350 to 500 CD4 cell count stratum (NA-ACCORD) is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19573724\">",
"    <span class=\"h2\">",
"     Patients with CD4 counts &gt;500 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are fewer observational data on the use of ART in patients with CD4 cell counts &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    compared with patients with lower CD4 cell counts and there are no randomized controlled trials that have examined the efficacy of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19573681\">",
"    <span class=\"h3\">",
"     NA-ACCORD study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two parallel analyses involving a total of 17,517 asymptomatic HIV-infected patients who had not received prior ART were analyzed based on outcome data from cohort studies conducted from 1996 through 2005 in the United States and Canada (ie, the NA-ACCORD study) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients were stratified into two groups according to their CD4 cell count at baseline (351 to 500 cells or &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    In each group, comparisons were made in the relative risk of death for patients who initiated therapy when the CD4 cell count was above each of the two thresholds (early therapy group) with that of patients who started therapy after their CD4 cell counts had fallen below these thresholds (deferred-therapy group).",
"   </p>",
"   <p>",
"    After adjustments for potential confounders, the two analyses demonstrated that deferred therapy was associated with increased mortality at both CD4 cell count thresholds, compared with early treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 8362 patients, 2084 (25 percent) initiated ART with a CD4 cell count of 351 to",
"      <span class=\"nowrap\">",
"       500/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      while the rest deferred therapy. There was a significant increase in the risk of death in the deferred versus early therapy group (relative risk 1.69, 95% CI 1.26-2.26). This analysis was based on a total of 375 deaths in both groups combined.",
"     </li>",
"     <li>",
"      Among 9155 patients, 2220 (24 percent) initiated ART at a CD4 cell count of more than 500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      while the rest deferred therapy. There was a significant increase in the risk of death in the deferred versus early therapy group (relative risk 1.94, 95% CI 1.37-2.79). This analysis was based on a total of 311 deaths in both groups combined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations of this observational study include the small number of deaths observed, the lack of data concerning cause of death and the possibility that patients who started ART at high CD4 cell counts may also have other \"health-seeking behaviors\" that contributed to the outcomes observed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/70\">",
"     70",
"    </a>",
"    ]. Furthermore, a substantial proportion of patients who deferred ART and yet maintained stable CD4 cell counts were not included in the analysis. It is, thus, unclear if this subset of patients would have also benefited from early treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/70\">",
"     70",
"    </a>",
"    ]. Finally, there is no information on drug toxicity, and the exact cause of death was only known for 16 percent of the patient population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2623104\">",
"    <span class=\"h2\">",
"     The START trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized controlled trial is in progress to address the timing of ART with respect to specific CD4 strata. Some experts are concerned that by the completion of this trial in 2015 or later, the results will no longer be relevant to contemporary clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the HIV treatment guidelines from the United States Department of Health and Human Services (DHHS) and the 2012 International Antiviral Society-USA Panel were revised to recommend that antiretroviral therapy (ART) be offered to all HIV-infected patients, including asymptomatic patients, regardless of immune status [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The strength of the evidence supporting this recommendation varies by the pre-treatment CD4 cell count, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Patients with a CD4 count &lt;350 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon evidence from randomized trials and observational studies, we recommend:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of ART in patients with a history of an AIDS-defining illness or a CD4 count &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      since ART is associated with a significant decline in risk of AIDS-related morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/13,14,24,67,69\">",
"       13,14,24,67,69",
"      </a>",
"      ]. The supporting data for these recommendations are more robust in patients with a CD4 count",
"      <span class=\"nowrap\">",
"       &lt;200/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      than in patients with a CD4 cell count between 201 and 350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5768851\">",
"       'Progression of immunologic decline'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Patients with CD4 counts between 350 and 500 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CD4 cell counts between 350 and 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of ART based on large observational studies supporting a clinical benefit in reducing AIDS and non-AIDS related complications. Patients should be advised of the potential risks and benefits of early intervention. Discussions should include exploration of the patient's readiness for lifelong treatment. A controlled clinical trial also demonstrated benefit of ART in reducing HIV transmission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patients with CD4 counts &gt;500 cells/mm3",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with CD4 counts greater than 500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    we suggest initiation of ART based on the following rationale:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncontrolled HIV viremia is associated with an increased risk of other comorbidities (including coronary artery disease, renal disease, neurologic complications, liver disease, and non-AIDS-associated malignancy) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Current ART regimens are better tolerated with lower pill burden and dosing frequency than regimens of the past",
"     </li>",
"     <li>",
"      ART, if properly taken, decreases the risk of sexual transmission of HIV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some observational data suggest a survival benefit with earlier initiation of treatment at CD4 cell counts &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    compared with delayed treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the potential benefit of ART needs to be balanced against the possible toxicities associated with long-term treatment. Long-term clinical outcomes in such patients are not available.",
"   </p>",
"   <p>",
"    An ongoing international clinical trial is examining the optimal time for asymptomatic HIV-infected patients with CD4 cell counts &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    to begin ART, although the results will not be available for several years. Thus, patient preference",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    \"readiness\" should play an important role in the decision to initiate therapy, pending results of the definitive trial. Patients should be advised of all the potential benefits noted above, but that the risk of an AIDS or non-AIDS related event secondary to untreated HIV infection is generally low among patients with CD4 cell count &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ;",
"    </span>",
"    careful consideration is suggested before a final decision is made [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/13,69\">",
"     13,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other patient subgroups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without HIV treatment, a small subset of patients (2 to 3 percent) are able to maintain normal CD4 cell counts for many years (\"long-term nonprogressors\") while an even smaller subset (0.5 to 1 percent) are able to maintain viral suppression with viral loads &lt;50",
"    <span class=\"nowrap\">",
"     c/mL",
"    </span>",
"    without ART (\"elite controllers\"). There are no clinical outcomes data supporting therapy in these patient subsets, although one study of 62 HIV controllers demonstrated significant CD4 cell count gains after initiation of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/73\">",
"     73",
"    </a>",
"    ]. If treatment is delayed there should be close monitoring of CD4 counts and viral load. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3302305\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART is recommended for all pregnant women to prevent perinatal HIV transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3302190\">",
"    <span class=\"h2\">",
"     Patients with opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment guidelines recommend early ART in patients with opportunistic infections, including tuberculosis (TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/3\">",
"     3",
"    </a>",
"    ]. Attention needs to be paid to drug interactions and the potential for complications related to the immune reconstitution inflammatory syndrome (IRIS) when treating TB and other opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/3\">",
"     3",
"    </a>",
"    ]. The timing of ART relative to treatment of the opportunistic infection will also vary depending on the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/54\">",
"     54",
"    </a>",
"    ]. One large randomized trial showed that initiation of ART within 12 days of treatment of an opportunistic infection (predominantly Pneumocystis and bacterial pneumonia) had better survival rates compared with those who delayed ART [",
"    <a class=\"abstract\" href=\"UTD.htm?9/35/9786/abstract/54\">",
"     54",
"    </a>",
"    ]. The timing of ART in central nervous system infections, such as cryptococcal meningitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3302241\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of treatment and monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TREATMENT READINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who initiates antiretroviral therapy (ART) should be willing and able to commit to lifelong treatment and should understand the benefits and risk of therapy and the importance of adherence.",
"   </p>",
"   <p>",
"    Each patient must be evaluated for their \"readiness\" to start daily antiretroviral therapy. The provider must devote time to educate the patient regarding the negative impact of poor adherence on the risk of drug resistance.",
"   </p>",
"   <p>",
"    A delay of ART is much more consequential among patients with low CD4 cell counts, AIDS-defining conditions, acute opportunistic infections, a baseline viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     c/mL",
"    </span>",
"    or a rapidly decreasing CD4 count (&gt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    per year). Treatment delay may also have significant consequences in patients with other comorbidities, such as HIV-associated nephropathy or viral hepatitis. When concerns persist about treatment readiness in a patient with advanced immunosuppression (&lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    a boosted protease inhibitor-containing ART regimen is preferred, which has a lower risk of drug resistance compared with other first-line regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H13#H13\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'NNRTI-based ART versus PI-based ART'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a decision is made to defer therapy, we suggest close clinical and laboratory monitoring (every three months) for evidence of thrush, weight loss, or rapid immunologic decline, which would indicate the need to rapidly initiate treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link&amp;anchor=H2#H2\">",
"     \"Considerations prior to initiating antiretroviral therapy\", section on 'Patient evaluation prior to initiation of antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"       \"Patient information: Starting treatment for HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5769935\">",
"    <span class=\"h2\">",
"     Potential benefits of antiretroviral therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary goal of combination antiretroviral therapy (ART) is to increase disease-free survival through suppression of HIV replication and improvement in immunologic function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CD4 cell count is the main indicator of immune function in patients who are HIV-infected and is the strongest predictor of disease progression with AIDS-defining complications and death. It is also one of the key factors in deciding whether to initiate chemoprophylaxis for opportunistic infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indicators of immune function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The supportive arguments for treating all HIV-infected patients, regardless of CD4 cell count, include expanded therapeutic options, greater potency of antiretroviral medications, and simplified dosing regimens, which facilitate adherence and improved quality of life, compared with earlier regimens. In addition, greater understanding of HIV pathogenesis suggests that untreated HIV infection is associated with an increased risk of other comorbidities.",
"     </li>",
"     <li>",
"      Arguments for delayed therapy include concerns regarding long-term toxicity, adherence, drug resistance and cost. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Rationale for treatment of all HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed treatment can also lead to subtherapeutic responses to treatment and immunologic decline. (See",
"      <a class=\"local\" href=\"#H5768830\">",
"       'Consequences of deferred treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Untreated HIV infection is also a risk factor for developing coronary artery disease, kidney disease, liver disease, neurocognitive deficits, and non-HIV-associated malignancy. Some of these observations may be related to HIV-induced proinflammatory cytokines, chronic inflammation, and T-cell activation, leading to end-organ damage. In a randomized controlled study of structured treatment interruptions, higher rates of mortality related to cancer, myocardial infarction, and liver-related deaths occurred in patients who stopped ART compared with those who continued ART. (See",
"      <a class=\"local\" href=\"#H5768904\">",
"       'Impact of ART on risk of other comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major public health-related rationale for early ART initiation is to prevent HIV transmission from an HIV-seropositive person to an HIV-seronegative sex partner and from an HIV-infected pregnant woman to an uninfected infant. These preventive health benefits may also apply to HIV discordant injection drug users who share drug paraphernalia. (See",
"      <a class=\"local\" href=\"#H5769013\">",
"       'Impact of ART on HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Treatment recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the introduction of potent three-drug combination antiretroviral regimens, epidemiologic data have demonstrated remarkable declines in morbidity and mortality among HIV-infected patients. The strength of the evidence for improved clinical outcomes increases as the CD4 count declines. (See",
"      <a class=\"local\" href=\"#H2622983\">",
"       'The clinical benefit of ART varies by baseline CD4 cell count'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines from the United States Department of Health and Human Services and the International Antiviral Society-USA Panel have been revised in 2012 to recommend treatment of all patients with HIV infection regardless of CD4 T cell counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a CD4 count &lt;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or a history of an AIDS-defining illness, we recommend initiating ART (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This recommendation is based on randomized controlled trial data demonstrating a significant decline in AIDS-related events and mortality and morbidity with HIV treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Patients with CD4 counts &le;200 cells/mm3'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Patients with a CD4 count &lt;350 cells/mm3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a CD4 cell count between 350 and 500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      we recommend initiating ART (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This recommendation is based on clinical trial data supporting a benefit in reducing AIDS- and non-AIDS-related complications and potential mortality-risk reduction. &nbsp;Patients should be advised of the potential risks and benefits of early treatment interventions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Patients with CD4 counts 350 to 500 cells/mm3'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Patients with CD4 counts between 350 and 500 cells/mm3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a CD4 cell count",
"      <span class=\"nowrap\">",
"       &gt;500/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      who are motivated to be treated, we suggest initiation of antiretroviral therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients should be advised that there is less evidence for the potential benefits of treatment at earlier stages of HIV infection, and the decision to treat needs to be balanced against potential toxicities of long-term therapy. A clinical trial, which is evaluating the safety and efficacy of ART among treatment-naive patients with CD4 cell counts&gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      is in progress. (See",
"      <a class=\"local\" href=\"#H19573724\">",
"       'Patients with CD4 counts &gt;500 cells/mm3'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Patients with CD4 counts &gt;500 cells/mm3'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy decreases the risk of HIV transmission",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physicians should explain to discordant heterosexual couples that viral suppression on ART decreases the risk of HIV sexual transmission to the HIV-seronegative partner substantially, but does not completely eliminate the risk, or the need for traditional preventive measures (eg, condoms). It is not known if viral suppression on ART would have a similar beneficial effect on transmission rates among men who have sex with men (MSM) and their HIV-seronegative partners. HIV treatment for prevention of transmission is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"       \"HIV treatment as prevention\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5768904\">",
"       'Impact of ART on risk of other comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ART is recommended in pregnant women by various guideline committees, regardless of CD4 cell count, to decrease rates of perinatal HIV transmission as well as to treat the mother. The evidence for this recommendation, the timing of ART relative to stage of pregnancy, and the choice of agents is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"       \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"       \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/1\">",
"      Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/3\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/4\">",
"      Attia S, Egger M, M&uuml;ller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/5\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/6\">",
"      Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/7\">",
"      Mellors JW, Mu&ntilde;oz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/8\">",
"      Egger M, May M, Ch&ecirc;ne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/9\">",
"      Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts &gt;/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/10\">",
"      Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/11\">",
"      Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/12\">",
"      Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010; 53:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/13\">",
"      Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick RK, Sabin CA, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/14\">",
"      Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/15\">",
"      Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/16\">",
"      Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/17\">",
"      Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/18\">",
"      Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/19\">",
"      Khanna N, Opravil M, Furrer H, et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008; 47:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/20\">",
"      Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/21\">",
"      Garc&iacute;a F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004; 36:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/22\">",
"      Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/23\">",
"      Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/24\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/25\">",
"      Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status. Clin Infect Dis 2008; 47:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/26\">",
"      Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/27\">",
"      Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/28\">",
"      Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/29\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/30\">",
"      Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/31\">",
"      Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/32\">",
"      Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002; 8:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/33\">",
"      Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/34\">",
"      Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006; 43:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/35\">",
"      Kalayjian RC, Franceschini N, Gupta SK, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/36\">",
"      Atta MG, Fine DM, Kirk GD, et al. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis 2007; 45:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/37\">",
"      Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the clinical management and treatment of HIV-infected adults in Europe. European AIDS Clinical Society.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/39\">",
"      Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/40\">",
"      Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/41\">",
"      Monforte Ad, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/42\">",
"      Marin B, Thi&eacute;baut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/43\">",
"      Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. Clin Infect Dis 2010; 50:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/44\">",
"      Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/45\">",
"      Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/46\">",
"      Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/47\">",
"      Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/48\">",
"      Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/49\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/50\">",
"      Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/51\">",
"      Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/52\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/53\">",
"      Degenhardt L, Mathers B, Vickerman P, et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/54\">",
"      Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/55\">",
"      Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/56\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/57\">",
"      Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/58\">",
"      Sterne JA, Hern&aacute;n MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/59\">",
"      HIV-CAUSAL Collaboration, Ray M, Logan R, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/60\">",
"      Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/61\">",
"      Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/62\">",
"      Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/63\">",
"      When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/64\">",
"      Rodr&iacute;guez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/65\">",
"      May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/66\">",
"      Ja&eacute;n A, Esteve A, Mir&oacute; JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008; 47:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/67\">",
"      HIV-CAUSAL Collaboration, Cain LE, Logan R, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/68\">",
"      Sabine C, Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/69\">",
"      Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/70\">",
"      Sax PE, Baden LR. When to start antiretroviral therapy--ready when you are? N Engl J Med 2009; 360:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/71\">",
"      Lundgren JD, Phillips AN, Neaton J. Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio. Clin Infect Dis 2009; 48:1162; author reply 1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/72\">",
"      Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/35/9786/abstract/73\">",
"      Okulicz JF, Grandits GA, Weintrob AC, et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 2010; 50:1187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3777 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9786=[""].join("\n");
var outline_f9_35_9786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATORS OF IMMUNE FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RATIONALE FOR TREATMENT OF ALL HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5768830\">",
"      CONSEQUENCES OF DEFERRED TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768837\">",
"      Risk of virologic failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768844\">",
"      Incomplete immunologic recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768851\">",
"      Progression of immunologic decline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5768904\">",
"      IMPACT OF ART ON RISK OF OTHER COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768950\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768957\">",
"      HIV-associated nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768964\">",
"      HIV-associated neurocognitive deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768971\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768978\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768985\">",
"      Hepatitis B infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768992\">",
"      Hepatitis C infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5768999\">",
"      Aging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5769013\">",
"      IMPACT OF ART ON HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5769072\">",
"      Discordant couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5769079\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5769086\">",
"      Injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3301982\">",
"      IMPACT OF ART ON RISK OF MORTALITY FROM OPPORTUNISTIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2622983\">",
"      THE CLINICAL BENEFIT OF ART VARIES BY BASELINE CD4 CELL COUNT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2622990\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Patients with CD4 counts &le;200 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patients with CD4 counts &ge;200-350 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients with CD4 counts 350 to 500 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19573724\">",
"      Patients with CD4 counts &gt;500 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19573681\">",
"      - NA-ACCORD study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2623104\">",
"      The START trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Patients with a CD4 count &lt;350 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Patients with CD4 counts between 350 and 500 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patients with CD4 counts &gt;500 cells/mm3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other patient subgroups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3302305\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3302190\">",
"      Patients with opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3302241\">",
"      ADVERSE EFFECTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TREATMENT READINESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5769935\">",
"      Potential benefits of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Antiretroviral therapy decreases the risk of HIV transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=related_link\">",
"      Dementia and delirium in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23929?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_35_9787="Signs of antipsychotic medication overdose";
var content_f9_35_9787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Atypical antipsychotic overdose: Signs and symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alpha-1:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dizziness, orthostatic hypotension, reflex tachycardia, miosis, nasal congestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Histamine-1:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS depression, appetite stimulation, hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Muscarinic-1:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Central",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Agitation, hallucinations, memory dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Peripheral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dry skin and mucous membranes, hypertension, constipation, mydriasis, blurry vision, tachycardia, urinary retention",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9787=[""].join("\n");
var outline_f9_35_9787=null;
var title_f9_35_9788="Entecavir lamiv refractory I";
var content_f9_35_9788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic improvement and change in Ishak Fibrosis Score at week 48, lamivudine refractory patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Entecavir 1 mg",
"        <br/>",
"        (n = 124)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lamivudine 100 mg",
"        <br/>",
"        (n = 116)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Histologic improvement (Knodell scores)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Improvement",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        55%",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        28%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No improvement",
"       </td>",
"       <td class=\"sublist_other\">",
"        34%",
"       </td>",
"       <td class=\"sublist_other\">",
"        57%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Ishak Fibrosis Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Improvement",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        34%",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        16%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No change",
"       </td>",
"       <td class=\"sublist_other\">",
"        44%",
"       </td>",
"       <td class=\"sublist_other\">",
"        42%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Worsening",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        11%",
"       </td>",
"       <td class=\"sublist_other\">",
"        26%",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Missing week 48 biopsy",
"       </td>",
"       <td>",
"        11%",
"       </td>",
"       <td>",
"        16%",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br/>",
"     * Patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score &ge;2).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     &ge;2-point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.",
"     <br/>",
"     &Delta; p&lt;0.05.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     For Ishak Fibrosis Score, improvement = &ge;1-point decrease from baseline and worsening = &ge;1-point increase from baseline.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9788=[""].join("\n");
var outline_f9_35_9788=null;
var title_f9_35_9789="BTM assays";
var content_f9_35_9789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bone turnover markers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Formation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Assay",
"      </td>",
"      <td class=\"subtitle1\">",
"       Circadian rhythm",
"      </td>",
"      <td class=\"subtitle1\">",
"       LSC",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       OC",
"      </td>",
"      <td>",
"       S*",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       21 percent",
"      </td>",
"      <td>",
"       Lack of standardization, rapidly degraded in serum, requires collection on ice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       BALP",
"      </td>",
"      <td>",
"       S*",
"      </td>",
"      <td>",
"       N",
"      </td>",
"      <td>",
"       28 percent",
"      </td>",
"      <td>",
"       Cross-reactivity with liver isoform (15 to 20 percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       P1NP/P1CP",
"      </td>",
"      <td>",
"       S*",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       21 percent/24 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Resorption",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       NTX",
"      </td>",
"      <td>",
"       U*,S",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       35 percent (S), 70 percent (U)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       CTX",
"      </td>",
"      <td>",
"       U,S*",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       30 percent (S), 80 percent (U)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       D-PYR",
"      </td>",
"      <td>",
"       U",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       26 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       PYD",
"      </td>",
"      <td>",
"       U*",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       36 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       HYP",
"      </td>",
"      <td>",
"       U",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Reflects bone resorption and dietary intake",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       TRACP5b",
"      </td>",
"      <td>",
"       S",
"      </td>",
"      <td>",
"       Y",
"      </td>",
"      <td>",
"       17 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OC: Osteocalcin; BALP: Bone-specific alkaline phosphatase; P1NP: N-terminal propeptide of type 1 procollagen; P1CP: C-terminal propeptide of type 1 procollagen; NTX: cross-linked N-telopeptide of type 1 collagen; CTX: cross-linked C- telopeptide of type 1 collagen; D-PYR: Free deoxypyridinoline; PYD: Free pyridinoline; HYP: Hydroxyproline; TRACP5b: isoform 5b of tartrate resistant acid phosphatase.",
"     <br>",
"      S: serum, collection of serum should be performed in the morning after an overnight fast; U: urinary excretion, collection of urine should be performed in the morning (usually second AM void, fasting); LSC: Least significant change; Circadian rhythm: higher in the early morning.",
"      <br>",
"       * Automated technology for measurement is available.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 2009; 63:19.",
"      <br>",
"       Scariano JK, Garry PJ, Montoya GD, et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre-and postmenopausal women. Clin Biochem 2001; 34:639.",
"       <br>",
"        Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24:561.",
"        <br>",
"         Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy:Impact of biological variability. J Bone Miner Res 1998; 13:1124.",
"         <br>",
"          Rosen HN, Parker RA, Greenspan SL, et al. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcified Tissue International 2004; 74:415.",
"          <br>",
"           Miller PD, Baran DT, Bilezikian JP, et al. Practical applications of biochemical markers of bone turnover:Consensus of an expert panel. J Clin Denistom 1999; 2:323.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9789=[""].join("\n");
var outline_f9_35_9789=null;
var title_f9_35_9790="Single breath DLCO";
var content_f9_35_9790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Single breath DLCO maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient quickly inhales a deep breath of test gas, holds his or her breath for 10 seconds, and then exhales quickly. The Jones method measures breathhold time (BHT) starting at 30 percent of inspiratory time (t",
"    <sub>",
"     I",
"    </sub>",
"    ) and extending to half of sampling time.",
"    <div class=\"footnotes\">",
"     RV: residual volume; TLC: total lung capacity.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Am J Respir Crit Care Med 1995; 152:2185.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9790=[""].join("\n");
var outline_f9_35_9790=null;
var title_f9_35_9791="Barretts post PDT";
var content_f9_35_9791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photodynamic therapy in a patient with Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segment of Barrett's esophagus two days after photodynamic therapy using Photofrin&reg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marta Davila, MD and Jacques Van Dam, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_35_9791=[""].join("\n");
var outline_f9_35_9791=null;
